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Abstract: SeaBioTech is an EU-FP7 project designed and driven by SMEs to create 19 
innovative marine biodiscovery pipelines as a means to convert the potential of marine 20 
biotechnology into novel industrial products for the pharmaceutical, cosmetic, aquaculture, 21 
functional food and industrial chemistry sectors. To achieve its goals, SeaBioTech brings 22 
together leading experts in biology, genomics, natural product chemistry, bioactivity testing, 23 
industrial bioprocessing, legal aspects, market analysis and knowledge-exchange. 24 
SeaBioTech targets novel marine endosymbiotic bacteria from unique and previously 25 
untapped habitats, including geothermal intertidal biotopes in Iceland, hydrothermal vent 26 
fields and deep sea oligotrophic basins of the Eastern Mediterranean Sea, and under-explored  27 
areas of Scottish coasts that are likely to be highly productive sources of new bioactive 28 
compounds.  This chapter describes the four- years of activity in the SeaBioTech project, 29 
which resulted in a robust, validated workflow suitable for evaluating unexplored activities in 30 
marine samples to prioritise potential products for a biotechnological pipeline. An improved 31 
integrated methodology involving metagenomics and metabolomics were extensively utilised 32 
to prioritise five extremophiles as potential antibiotics, anti-cancer drugs and as novel drugs 33 
against metabolic diseases as well as new pharmaceutical excipients to the pipeline. A 34 
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centralised biobank repository, which included a database of information, was established for 1 
future bioprospecting activities. For future marine bioprospecting activities, a harmonised 2 
legal position was put together in collaboration with other EU-FP7 blue biotechnology 3 
projects. 4 
 5 
SeaBioTech is funded by the European Commission within its FP7 Programme, under the 6 
thematic area KBBE.2012.3.2-01 with Grant Number 311932. 7 
1 Introduction 8 
The 48-month SeaBioTech project was designed and driven by SMEs to convert the huge 9 
potential from as yet underdeveloped marine biotechnology into novel bioactive 10 
pharmaceuticals (anti-cancer, anti-parasitic, antibiotic, and against metabolic diseases), 11 
cosmetic and  food (antioxidant) as well as industrial chemistry (biocatalysts, reagents) 12 
sectors. The project made use of the biodiversity from marine extreme environments. Such 13 
environments are characterized by geochemical and physical conditions at the edges of the 14 
compatibility with life, and they are colonized by highly adapted organisms called 15 
extremophiles. These can provide unique chemicals and novel enzymes that have enormous 16 
potential because they maintain their performance even in harsh industrial process conditions. 17 
However, there are significant bottlenecks that presently restrict the marine biodiscovery 18 
pipelines relating to: 19 
 limited availability of collections of marine extremophiles and little knowledge of 20 
their potential use in biotechnology (lack of qualitative and quantitative data with 21 
respect to the application performance) 22 
 limited transfer of knowledge from fundamental research into technically realizable 23 
and cost-effective products and technologies 24 
 technical hurdles with methods and processes, including in the cultivation and storage 25 
of organisms, and in extraction, isolation and characterization of bioactive 26 
components 27 
 lack of industrial scale production techniques for marine substances, based on the 28 
limited understanding of the process physiology of the native producer microorganism 29 
To develop efficiently marine biodiscovery pipelines and provide access to sustainable and 30 
economical production methods, SeaBioTech has tackled five key challenges (Figure 1) with 31 
an integrated approach combining access to unique marine biodiversity, innovative culturing 32 
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approaches, genomic and metagenomics analyses coupled with metabolomics, natural 1 
product chemistry, bioactivity evaluation and industrial bioprocessing along with legal 2 
aspects, market analysis and transfer of knowledge. SeaBioTech has not only increased the 3 
number of marine-based products but also their success rate for future commercialization. 4 
SeaBioTech’s research and technological progress was completely within the framework 5 
provided by the participating SMEs relating to their definition of product opportunities and 6 
proof-of-concept demonstration activities. 7 
1.1 SeaBioTech has put together a marine biodiscovery pipeline using 8 
an integrated approach.  9 
The project’s innovation plan corresponded to the following scientific, technical and 10 
technological challenges as shown in Figure 1: 11 
Challenge 1: The quality of marine resources: the approach to resource quality begun 12 
by standardizing the sampling process from unique and previously untapped habitats, which 13 
included geothermal intertidal biotopes in Iceland, hydrothermal vent fields and deep sea 14 
oligotrophic basins of the Eastern Mediterranean Sea, and unsampled areas of Scottish coasts 15 
that are likely to be highly productive sources of new bioactive compounds. The marine 16 
resources also included the partners’ existing biobanks (UK’s Culture Collection of Algae 17 
and Protozoa, MATIS’s Icelandic collection, Eastern Mediterranean Sea collections) as well 18 
as new in situ sampling. The SeaBioTech sampling process guaranteed the quality of marine 19 
resources for further industrial development, including identification of marine 20 
microorganisms and their variability based on genomics and metagenomics. This project also 21 
integrated the critical aspect of the maintenance of the sampled species with their intrinsic 22 
quality and their secondary metabolites, by developing special cultivation media and storage 23 
conditions. 24 
Challenge 2: The improvement in technical aspects: to improve marine biodiscovery 25 
and reassure industries about its feasibility, SeaBioTech perfectly combined metabolomics 26 
assisted by systems biology and functional bioassays to increase the ability to disclose 27 
positive hits with an economical and faster approach: an affordable, innovative and efficient 28 
method to separate, elucidate the structure, and identify the bioactive metabolites. 29 
Challenge 3: Sustainable modes of supply of raw materials for the industries: the last 30 
technical brick for industries is the sustainability of these newly discovered raw materials not 31 
only at lab scale but also at industrial scale. Thus, SeaBioTech benefited from the power of 32 
well-controlled metabolic engineering of interesting organisms (bacteria, microalgae, 33 
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cyanobacteria) increasing the yield of bioactive metabolites at lab scale and multiply this 1 
yield through fermentation technology at industrial scale to deliver promising enzymes, 2 
polymers and small molecules as industries need. 3 
 4 
 5 
Figure 1. Concept of SeaBioTech, showing the interactions between the five key challenges to 6 
be faced in order to improve marine biodiscovery pipelines. The first three challenges in the 7 
inner most circle concerns the primary goals of the project that includes: 1) the quality of 8 
marine resources; 2) The improvement in technical aspects; and 3) a sustainable mode of 9 
supply of raw materials for the industries. The transversal activities involving challenges on 10 
4) the legal aspects and 5) the access to marine biotechnology data are the second level 11 
represented on the outer circle.  12 
 13 
The second level embraces the last two challenges as transversal activities: challenge 4, the 14 
legal framework was necessary to secure the access to marine resources, their sustainable use 15 
and their exploitation process; and challenge 5, the access to a marine biotechnology database 16 
and biobank. 17 
Challenge 4: The whole biodiscovery process was completed by the clarification of 18 
all legal aspects to gain visibility and efficiency for industry. SeaBioTech coordinated the 19 
legal procedures with national, European and international authorities/stakeholders to propose 20 
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harmonization of the legal process related to marine bioprospecting, biodiscovery and marine 1 
biotechnology for commercial purposes. 2 
Challenge 5: To crystalize this innovative approach, SeaBiotech created a centralized 3 
tool to describe the whole marine biodiscovery pipeline including available biobanks, the 4 
identified marine organisms, compounds and extracts, the cutting-edge methods in 5 
identification, elucidation, metabolic engineering to be further used for industrial purposes 6 
with all related procedures on legal process for companies, academia, and legal authorities. 7 
1.2 SeaBioTech is an industry-driven project.   8 
Contrary to previous approaches, SeaBioTech commenced by defining industry needs 9 
- more specifically SMEs’- across marine biodiscovery pipelines. To achieve the overall goal 10 
of making sustainable marine-based compounds more attractive for industries along with 11 
shortened time to market, the specific objectives of SeaBioTech are to: 12 
 provide a pipeline of commercially viable products based on relevant 13 
bioactivity screening of samples of marine origin;  14 
 develop efficient standardized processes and methods across the biodiscovery 15 
pipeline; 16 
 introduce industrial bioprocessing methods suitable for commercial production 17 
of marine-sourced materials; 18 
 clarify, harmonize and potentially simplify the legal aspects related to marine 19 
biodiscovery processes; 20 
 create a central EU platform and biobank based on an integrated approach to 21 
biodiscovery pipelines for future use by other consortia, academia and 22 
companies. 23 
1.3 Identification of industry needs: providing an industry-driven 24 
project 25 
It is easier to put the key challenges for marine biotechnology into an addressable 26 
context by defining what the concrete output from marine biodiscovery pipelines might be. 27 
Therefore, SeaBioTech started with a thorough market analysis of the various industrial 28 
sectors that are relevant to the partners, particularly the SMEs. This clearly indicated where 29 
there is a need for products that go beyond the current state of the art. This in turn provided 30 
the perspective for the technical challenges and highlighted the needs for improvements.  All 31 
SMEs within SeaBioTech were committed to the concept of marine bioprospecting as a 32 
strategy to provide them with key future products that are beyond the state of the art and 33 
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enhanced their business competitiveness. The SeaBioTech project was specifically designed 1 
to deliver to the SMEs’ progress, eliminating or dramatically reducing bottlenecks to allow 2 
the SMEs to develop innovative products for the world market. It is important to note that 3 
success of the project must show other SMEs and industries what is technically feasible and 4 
economically attractive from marine biotechnology – SeaBioTech will represent a sustainable 5 
and reproducible model for the European biotech industry. The companies involved in 6 
SeaBioTech are focused on the biodiscovery pipelines of three compound categories: (1) 7 
polymers having bioactivities such as wound healing, optic turgor in lenses and 8 
pharmaceutical additives driven by Marine Biopolymers (MBL) and MATIS; (2) enzymes 9 
having bioactivities such as transaminases, reductases, etc driven by Ingenza, Prokazyme, 10 
Lund and MATIS; and (3) small molecules having bioactivities as therapeutics (antibiotic, 11 
anti-cancer, etc) driven by Axxam, HDL, PHARMAQ, SIPBS and UWUERZ. Each step of 12 
the biodiscovery pipeline related to these three types of compounds and the related target 13 
application explored to provide innovative ingredients for novel industrial products. The 14 
whole SeaBioTech biodiscovery process was informed by Rothwell's coupling model of 15 
innovation (Rothwell, 1992) so that there is a regular interplay between understandings of 16 
market needs and technical ‘pull’.  17 
SeaBiotech | Edrada-Ebel et al. 
 
Page 7 of 71 
 
2 Methodology and Overall strategy 1 
 2 
Work packages (Figure 2) were set up to organise a schematic flow of materials and data 3 
between partners. In order to achieve the desired outcomes of a greatly improved pipeline of 4 
products from marine biotechnology, the first step is to identify clearly the market 5 
opportunities for the companies involved in SeaBioTech and the precise bottlenecks they 6 
have to solve to target their respective markets. The target applications of the consortium 7 
involved pharmaceuticals, fish health, food, cosmetic, chemical and industrial in WP1 8 
(Definition of product opportunities, dissemination, exploitation plan and IPR). WP1 formed 9 
the basis of the subsequent research activities in WP3-7. Through an understanding of market 10 
and technical requirements, several partners each contributed to the definition of demand 11 
statements for their own industrial sectors. In addition, WP1 integrated the IPR management. 12 
In parallel, WP2 (Sampling process) created a huge collection of novel microbes and 13 
microbial consortia for genome and metagenomic analyses and to facilitate their 14 
biotechnological exploitation. WP2 led by HCMR collected information from all culture 15 
Figure 2. The SeaBioTech Work Packages 
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collections available from partners, isolated novel microbes from several diverse 1 
environments and organisms and facilitated their exploitation at WP3/WP4 for bioactivity 2 
screening and genomic analyses. WP2 also prepared samples that can be screened in WP3 3 
(Detection and characterisation of commercially relevant bioactivities) led by AXXAM. 4 
WP3 was responsible for detecting bioactivities that were selected as priority commercial 5 
targets in WP1 by testing samples provided by WP2 and WP4. WP3 provided the detailed 6 
bioactivity assessments to guide isolation of substances with commercial potential. WP4 7 
(Genomic and metagenomic bioprospecting) led by the University of Wuerzburg used 8 
molecular techniques to pinpoint novel enzymes of commercial interest and isolated the 9 
genes for synthetic pathways for novel small molecules for testing in WP3. This also allowed 10 
structural variations to be prepared as a mean to improve bioactivities. A number of high-11 
throughput solid phase screening in vitro and direct selection methods in vivo was applied in 12 
this work package to identify novel enzymatic activities of interest from metagenomic 13 
libraries constructed from genomic DNA derived from marine micro-organisms. WP5 14 
(Natural products metabolomics) led by SIPBS was the analytical arm of the consortium, 15 
undertaking dereplication studies on microbial extracts of interesting isolates from WP2 and 16 
those screened for the presence of biosynthetic clusters from WP4. WP5 isolated and 17 
structure elucidated the bioactive natural products determined in WP3. Along with WP6, their 18 
sustainable production by the microbial cultures was optimised through metabolomics tools. 19 
When interesting metabolites were confirmed in WP5 in collaboration with WP3, organisms 20 
could be engineered to guarantee sustainability of the interesting metabolites in WP6 (Genetic 21 
and metabolic engineering) also led by SIPBS. WP6 undertook the research that will allow 22 
organisms producing targeted substances to be maintained at the laboratory scale. It also 23 
performed genetic manipulation to produce structural variants of the target substances as a 24 
means to improving their commercial properties. When lab scale is validated, it is essential to 25 
integrate at industrial scale. WP7 (Industrial bioprocessing) led by MATIS focused upon 26 
developing rapid and robust methods for the industrial exploitation of microbial and enzyme 27 
based marine products. In order to achieve this, WP7 tasks will link very closely to those in 28 
WP5 (Metabolomics) and WP6. A sub-task in WP7 consisted of a series of projects 29 
conducted to test the viability of the outputs from earlier WPs as the basis for new 30 
commercial products relevant to various partners, including pharmaceutical, functional foods, 31 
novel enzymes, and research tools. WP8 (Marine policy, legal and ethical issues) ensured 32 
that the SeaBioTech project develops in accordance with all relevant national and 33 
international legislation governing bioprospecting and the marine environment. The WP’s 34 
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main goal is to contribute to the on-going development of the legal framework for marine 1 
bioprospecting, and ensured dissemination of the project results to the scientific community, 2 
to public and political stakeholders. The key task was the creation of an EU platform 3 
allowing access to data from SeaBioTech and to physical samples in SeaBioTech’s biobank. 4 
WP9 (Project Management) deployed and implemented management best practices through a 5 
clear focus on both strategic and operational administration. 6 
23 The SME partners and their activities 7 
In this section we present the roles and contributions of SeaBiotech’s partners from 8 
the industry as well as theSME’s mutual gain from the consortium. With the analysis of 9 
market opportunities and the generation of an initial exploitation plan, the respective SMEs 10 
defined specific commercial goals, and strategies to reach these goals within SeaBioTech 11 
project. The exploitation plan also further underlined the importance of collaboration between 12 
the company and RTD partners as a key to the successful exploitation of the opportunities 13 
and potential of the SeaBioTech project. Through this EU-funded partnership, the SMEs 14 
made agreements with academic and research institutions in the consortium for the licensing 15 
of products that will be offered by the respective companies with shared revenues according 16 
to specific agreements. The strategy was to exploit potential collaborations with academic 17 
groups in SeaBioTech as a new business scheme for increased portfolio of products for the 18 
research laboratory market in Europe and elsewhere. SeaBioTech brought together significant 19 
members of the fields of marine biotechnology and biocatalysis experts for the first time and 20 
delivered industrially useful novel biocatalysts by developing highly innovative and powerful 21 
screening and selection technologies and novel, high yielding, scalable and economic enzyme 22 
production systems. Some of the SMEs had taken steps to further develop the successful 23 
strategy of alliance with its partners in the SeaBioTech project with continued collaboration 24 
that will extend well beyond the lifetime of the SeaBioTech project. Very good collaboration 25 
with both academia and SME's that will continue after the end of the project is one of the 26 
main and high impact results for the SMEs. SME partners have communicated with various 27 
potential end users and current market producers to develop collaborations for the future 28 
development of the compounds. As a next step to support the potential commercialization of 29 
bioactive compounds, further funding will be required to undertake the studies to better 30 
understand mechanism of action, develop a suitable patient stratification strategy and to 31 
assess tractability for conventional medicinal chemistry. However, one disadvantage for the 32 
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academic partners is that, a SME will not release any publication on the compounds for 1 
reasons of commercial sensitivity especially if patents are to be filed in the coming years.   2 
2.13.1 Prokazyme (PKZ) 3 
PKZ has been engaged in commercialising enzymes that have advantageous 4 
biochemical properties over competing products. In this project, their work was focused on 5 
developing enzymes from extremophiles that were recognised as being potentially valuable in 6 
many applications. However, very few novel enzymes from the hundreds reported in the 7 
literature reach the market.  Generally, the limitations in this area are difficulties in obtaining 8 
large enough supplies in a sustainable way and challenges in producing the enzyme to a high 9 
standard of purity in an economically attractive manner. PKZ saw opportunities in 10 
bioprospecting the unique genomic resources it had access to through the SeaBioTech gene 11 
banks and in the enormous, untapped marine biodiversity sampled through SeaBioTech. The 12 
SeaBioTech project offered significant progress above the state of the art on new marine 13 
compounds (particularly oligosaccharides), as well as enzymes, increasing PKZ existing 14 
offerings of specialized extremophilic enzymes for the R&D market. PKZ has made strategic 15 
plans for future commercial production of enzymes on an economical large scale. As part of 16 
this future strategy, it is the intention that the production of enzymes shall be transferred from 17 
PKZ to a subsidiary company. PKZ and MATIS have initiated a large research proposal with 18 
a consortium consisting of 15 partners in Europe. The research proposal, “Virus-X: Viral 19 
metagenomes for Innovation Value”, has secured a EUR 8 million funding from the 20 
European Union under the Horizon2020 framework. PKZ will coordinate the project and 21 
within the project extend its collaboration with specific partners from the SeaBioTech 22 
project. A grant agreement was made during this period with the European Union for the 23 
funding and the project started on April 1st 2016 and will be continued until March 30th 24 
2020. 25 
2.23.2 PHARMAQ 26 
PHARMAQ specialises in vaccines and therapeutics for farmed fish. A key need for 27 
aquaculture is to have effective anti-parasitic agents that are potent and selective against the 28 
target parasite while having no damaging effects on the environment. Most of the anti-29 
parasitic products available within aquaculture today are derived from known pesticides 30 
developed for terrestrial applications and some of these are limited by their toxicities. 31 
Hence, SeaBioTech offered a unique opportunity to search for bioactives from novel and 32 
unexplored sources, particularly by uncovering potential new therapeutics for aquaculture 33 
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applications and defining their suitability for commercial development. The SeaBioTech 1 
project yielded good results for PHARMAQ. SeaBiotech developed an HTS (high-throughput 2 
screening) assay directed against a target special for salmon lice. The assay was very valuable 3 
in screening large libraries in the search for new actives against one of the most devastating 4 
parasites in aquaculture. Some compounds with effect against salmon lice have been 5 
identified. Although the effect has so far only been identified at a relative high 6 
concentrations, the compounds were worthy of further examination. 7 
2.33.3 Marine Biopolymers Ltd (MBL) 8 
MBL supplies chemicals derived from marine sources, including alginates and 9 
polyphenols. While the potential value of compounds such as alginate and fucoidan is well 10 
recognised, their widespread use is limited by technical problems: (i) low quality and low 11 
yields from existing extraction methods; (ii) lack of higher performance purification 12 
approaches to provide products at the ‘fine chemical’ standard; and (iii) incomplete analysis 13 
and characterisation of isolated components. MBL sees huge product opportunities arising 14 
out of the collaborative work in the SeaBioTech project. During the project’s lifetime, MBL 15 
focused on defining the company’s interests on polysaccharide compounds and their growing 16 
market demand. In addition to the polysaccharides, the sampling events of macro- and micro- 17 
epiphytes have presented interesting and new chemistry and bioactivity across a range of 18 
compounds. MBL continued sampling of key macroalgal species to develop seasonal 19 
metabolomic data. It has achieved commercially valuable improvements arising from the 20 
SeaBioTech consortium. An initial market analysis was also explored defining the potential 21 
market size/demand and market areas the compounds could feed into, whether that be as a 22 
stand-alone product or as an ingredient in a current or new formulation. Although MBL 23 
initially had a strong focus on polysaccharides, it was clearly observed that there are 24 
additional compounds that MBL now plan to commercialise over the coming years subject to 25 
the availability and success of appropriate follow-up funding mechanisms.  26 
2.43.4 Ingenza (IGZ) 27 
SeaBioTech provided opportunity to discover new biocatalysts with industrially 28 
relevant substrate specificities for integration with IGZ’s current bioprocesses for the 29 
manufacture of enantiopure chiral amines, unnatural amino acids and other chiral chemical 30 
platforms. The most promising identified biocatalysts were developed using economic and 31 
scalable fermentation and bioprocess systems. Further development and implementation of 32 
inABLE® which is IGZ’s combinatorial genetics technology for the efficient and selective 33 
SeaBiotech | Edrada-Ebel et al. 
 
Page 12 of 71 
 
assembly of DNA expression vectors, took place in the project. These technologies were key 1 
tools for improvement of strain construction and screening, and have been used and 2 
developed through SeaBioTech and the technology is of core importance to all of IGZ’s 3 
commercial interests.  4 
The screening of both alternative metagenomics libraries and those of the work 5 
package partners for new and novel enzymes of commercial interest to IGZ was carried out. 6 
This allowed expression constructs to be made and screens to be developed in WP6, which 7 
led to subsequent production processes in WP 7. These generic fermentation protocols which 8 
had been developed previously were then implemented to test the growth and expression of 9 
positive hits which were highlighted in the subsequent screening of the work package 10 
partner’s databases. These novel marine enzymes were cloned into an industrially relevant E. 11 
coli strain using inABLE® compatible parts. Further optimisation of the expression of these 12 
strains has been carried out in shake flasks followed by activity assays of the successfully 13 
expressed enzymes. Based on these results, fermentation development has been implemented, 14 
linking into the deliverables required for WP7. A production process of the most successful 15 
enzymes was implemented and scaled up during the course of SeaBioTech.  16 
2.53.5 Horizon Discovery Ltd (HDL) 17 
HDL has been developing new drug discovery opportunities in the cancer field 18 
through its creation of unique cell lines that are engineered to represent particular forms of 19 
cancers. HDL saw great application in screening marine-derived natural products from the 20 
project to therapeutically ‘deorphan’ the cancer genome. HDL’s  expertise on cell-based 21 
screens using genetically defined human disease models represented the ideal approach to 22 
directly find unexpected uses for naturally bioactive molecules from the project to such 23 
‘orphan-targets’, where the full complexity of cell biology was screened in a rational manner 24 
to find novel cancer-selective agents. Ultimately, HDL was able to show that several 25 
fractions containing single compounds had a marked ability for specifically killing cancer 26 
cells via inducing apoptosis. This is proof-of-principle that bioactive compounds isolated 27 
from these particular classes of marine organisms may have at least some of the required 28 
characteristics for exploitation in the oncology arena.  29 
2.63.6 AXXAM 30 
AXXAM is a lead compound discovery company that services the pharmaceutical, 31 
agrochemical and life sciences sectors. AXXAM was SeaBioTech’s link to the mainstream of 32 
pharmaceutical development and marketing companies. AXXAM provided a panel of 33 
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functional assays that detect activities relevant to key diseases (infections, inflammatory 1 
diseases, chronic pain, etc.). AXXAM supported the hit discovery programmes of 2 
SeaBioTech by performing in total 11 screening campaigns on a comprehensive number of 3 
927 crude samples of marine origin on an array of cell-based and enzymatic assays, which 4 
was refined based on the obtained results to seven assays (TRPA1, TRPM8, TRPV1, PPARα, 5 
EL, HDAC6, HDAC2) suitable for high-throughput screening of complex extracts. These 6 
functional assays were developed to measure the activity of validated targets in three main 7 
disease indications: cancer (HDAC6 and HDAC2), metabolic syndrome (EL, PPARα) and 8 
pain (TRPA1, TRPM8, TRPV1). At the end of the primary screening activity, 287 crude 9 
extracts were confirmed as primary hits, distributed as follows: TRPA1 (12), TRPM8 (37), 10 
PPARα (36), HDAC6 (81), HDAC2 (3), EL (118). In collaboration with WP2-WP5, 31 crude 11 
extracts derived from 17 marine microorganisms were prioritized and included in the 12 
SeaBioTech pipeline. A subset of 15 crude extracts was fractionated by WP5 and 629 13 
fractions were subjected to screening against the primary assays TRPM8, TRPA1, PPARα, 14 
HDAC6 and EL, respectively. The support to dereplication activities led to the identification 15 
of 148 fractions containing the sought bioactivity against the following primary targets: 16 
TRPA1 (9), TRPM8 (5), PPARα (5), HDAC6 (76), EL (53). Remarkably, one series of 27 17 
fractions derived from the crude extract SBT0541 (Algoriphagus marincola) was confirmed 18 
to contain negative modulators of the catalytic activity of Endothelial Lipase (EL). Among 19 
them, 8 fractions contained pure compounds which were identified by WP5, which allowed 20 
the definition of a preliminary structure-activity relationship. This finding appeared 21 
consistent with the targeted enzyme Endothelial Lipase (EL), which physiologically releases 22 
fatty acids from phospholipids in HDL particles. The compounds displayed a dose-dependent 23 
inhibition on EL, with partial inhibition at the highest compound concentrations tested. The 24 
negative modulation of the EL activity identified by AXXAM has never been reported in 25 
literature.  26 
In addition, the collaboration between SIPBS, AXXAM and PHARMAQ has been 27 
reinforced throughout the SeaBioTech project to promote an integrated hit discovery program 28 
for the identification of marine compounds with anti-parasitic activity directed against 29 
Lepeophtheirus salmonis, a major threat for aquaculture. Three high-throughput assays made 30 
available by AXXAM (TRPA1, TRPV1 and voltage-gated Na-channel) were applied as pre-31 
selection tools for the prioritization of crude extracts and fractions to be tested by 32 
PHARMAQ with the low-throughput phenotypic assay on living parasites. In total, AXXAM 33 
screened over 750 crude extracts for this purpose, which generated a list of 135 hits 34 
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prioritized for testing at PHARMAQ. A number of these hits were confirmed for their 1 
parasiticidal activity on L. salmonis, and further characterization is ongoing at PHARMAQ 2 
on a subset of fractions to identify the pure compounds responsible for the sought bioactivity. 3 
Newly discovered and underexplored species of marine microorganisms were 4 
demonstrated to be effective sources of novel therapeutics to be progressed to address unmet 5 
medical needs and threatening parasitic infections for aquaculture. Thus, the availability of 6 
novel therapeutics for human health and aquaculture will directly contribute towards 7 
improving quality of life, health, employment and economic strength. In addition, the 8 
knowledge gained through SeaBioTech concerning the assay development and screening of 9 
complex marine extracts may directly or indirectly translate into new opportunities for the 10 
CROs to expand their potential market and for pharmaceutical and life science companies to 11 
undertake novel R&D projects. 12 
34 Addressing the Challenges through Scientific Breakthroughs 13 
3.14.1 Challenge 1: Access, sampling, storage and quality maintenance 14 
of marine resources present in extreme environments and sponge 15 
symbionts 16 
The characterization of natural microbial communities in extreme environments has been a 17 
major challenge for microbial ecology. Considering that 71% of the earth’s surface has an 18 
average depth of 3800 m, deep-sea environments have attracted much interest as niches of 19 
microbial life with considerable exploitation potential. Extreme environments are 20 
characterised by geochemical and physical extremes, at the edges of the compatibility with 21 
life. Many diverse extreme environments have been described, and they are colonized by 22 
highly adapted organisms called “extremophiles” (Rothschild & Mancinelli 2001). These 23 
organisms fall into a number of different classes that include thermophiles, acidophiles, 24 
alkalophiles, psychrophiles, barophiles (piezophiles) etc, depending on their ecological niche 25 
(Demirjian et al. 2001). Because of their unique metabolic adaptations to their environment, 26 
the extremophiles are considered to have an enormous potential for unique biotechnological 27 
applications because they allow the performance of industrial processes even in harsh 28 
conditions, under which conventional proteins are denatured or inefficient (Niehaus 1999, 29 
Rothschild & Mancinelli 2001). Consequently, these unique properties have resulted in 30 
several novel applications of enzymes in industrial processes. Similarly, the novel 31 
biochemistry of extremophiles is predicted to generate novel chemicals that are distinct in 32 
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structure from those from more conventional organisms. Hence, such compounds are likely to 1 
be useful in drug discovery applications. However, only a minor fraction of extremophile 2 
organisms has been exploited. Very few sources have been explored to date so that there was 3 
a rich potential for SeaBioTech to go beyond the state of the art so long as it is possible to 4 
obtain samples of a suitably high quality.  5 
The first aspect of the ‘quality of marine resources’ challenge was simply to obtain 6 
access to extremophile samples from the marine environment. Companies seeking a wide 7 
range of biodiversity from extreme marine environments would struggle because such 8 
sources are not commercially available currently. The Australian Institute of Marine Sciences 9 
is no longer supporting access to its collections; MarBank in the University of Tromsø in 10 
Norway has a limited collection, which is not openly available; the National Cancer Institute 11 
in the USA provides access to a small number of marine-derived samples. There appears to 12 
be a single commercial source: Magellan Bioscience in the USA, which works 13 
collaboratively with other companies through offering access to its collection of marine 14 
microbes. However, few of these are extremophiles. Beyond that are the scattered ‘ad hoc’ 15 
collections found in some university departments and research institutes. The SeaBioTech 16 
project had access to several extreme environments that have not yet been explored for 17 
commercially relevant bioactivities and had capitalised on untapped resources associated with 18 
some of the participants, notably microbial symbionts from sponges and the UK’s Culture 19 
Collection of Algae and Protozoa (CCAP). The benefits of these sources are explained below. 20 
3.1.14.1.1 Geothermal intertidal biotopes in Iceland 21 
Intertidal biotopes harbour a large diversity of ecologically and biotechnologically interesting 22 
organisms. This is a highly dynamic environment subject to constant periodic disturbances 23 
with steep gradients of temperature, mineral composition and salinity. The organisms need to 24 
tolerate periods of dryness and even exposure to harsh UV radiation during low tide. 25 
Temperature gradients are manifested most clearly in the contrast between the hot fluid in 26 
geothermal coastal hot areas and the cold seawater, and the hot spring water may have high 27 
levels of sulphur compounds and toxic metals. These habitats have rich invertebrate fauna 28 
and often covered by a profusion of algal vegetation containing various complex recalcitrant 29 
polysaccharides that may be utilized by a variety of microbes, factors influencing the 30 
microbial diversity. Photosynthetic microbial mats are abundant in these areas and many hot 31 
springs may have both chemo-litho-autotrophic and photosynthetic organisms as primary 32 
producers, adapted microbes to unique conditions. Rare species in these areas include various 33 
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obligate heterotrophs, but their presence may be masked by the dominant primary producers 1 
and therefore they are not easily studied or accessible for biotechnological exploitation. The 2 
unique geothermal environments on the coasts of Iceland sustained a relatively high diversity 3 
of microorganisms and unique organisms not previously exploited as a resource for bioactive 4 
microbial metabolites or enzymes of industrial interest. Past studies revealed a great number 5 
of novel organisms indicating that geothermal habitats harbour an enormous diversity still to 6 
be isolated, characterized and exploited (Staley & Konopka 1985; Roszak 1987; Amann 7 
1995; Skirnisdottir 2000).  Within the SeaBioTech project, a total of 49 samples were 8 
collected from coastal geothermal sites in Iceland, primarily from photosynthetic microbial 9 
mats and also from polysaccharide enrichments in situ and a total of 194 strains were 10 
isolated: 122 from Laugarvík, 47 from Yngingarlindir and 25 from Reykhólar. Numerous 11 
strains representing novel species and genera were isolated, especially from Yngingarlindir. 12 
Alginate degrading anaerobic isolates from Reykhólar were close to the genus Clostridium 13 
and five of them were selected for whole genome sequencing and genome annotation 14 
analyses in WP4. A preliminary study of the species composition of Cyanobacteria from the 15 
clone sequences from the YL samples was performed and the largest taxon contained several 16 
species representing distant (88-95% 16S rDNA similarity) relatives of Geitlerinema sp. 17 
within the Oscillatoriales. A similar study on the composition of Cyanobacteria in four of the 18 
Laugarvík biomat samples revealed the majority of sequences belonged to a filamentous 19 
Leptolyngbya sp highly related to a Leptolyngbya sp. found in arctic hot springs in 20 
Greenland. Results from culture independent biodiversity studies in Yngingarlindir and 21 
Laugarvík indicated novel species of Cyanobacteria. Seven Cyanobacteria strains were (M24-22 
M36) isolated from mat samples and identified. Strains of interest (32) were selected for 23 
extractions in WP3. The extracts (62) and relevant control samples (6) were labelled and sent 24 
to the relevant partners for bioactivity screening. Based on novelty, 39 strains were selected 25 
for whole genome sequencing and annotations in WP4 & WP6. From the total of 39 strains, 26 
38 strains were sequenced and their genomes annotated. 27 
3.1.24.1.2 Deep sea oligotrophic basins and hydrothermal vent fields in the Eastern 28 
Mediterranean Sea 29 
The Eastern Mediterranean Sea is a dynamic region with unique hydrographic and 30 
geomorphologic features (e.g. the Mediterranean Ridge, Hellenic Volcanic Arc, deep abyssal 31 
plains, seamounts, deep anoxic hypersaline basins, hydrothermal vent areas, submarine 32 
volcanoes and mud volcanoes, methane and hydrogen sulphide cold seep sites, etc.). The 33 
subduction of the African plate below Europe has resulted in the formation of the 34 
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Mediterranean Ridge and deep basins as well as volcanism in the Hellenic Volcanic Arc. 1 
Major hydrothermal systems are found along the Hellenic Volcanic Arc at Methana, Milos, 2 
Santorini and Nisiros islands (Dando et al. 2000). Venting gases in these areas contain 3 
substantial amounts of CO2, H2, and H2S, thus providing the chemical environment for 4 
chemolithoautotrophic primary production (Dando et al., 1995). Steep chemical and 5 
temperature gradients (Wenzhöfer et al., 2000) create diverse niches for numerous microbial 6 
populations. Initial screening studies of microbial diversity indicated a high spatiotemporal 7 
variation in microbial community structure (Sievert et al., 1999) combined with highly 8 
diverse bacterial communities, with less than 33% of 16S rDNA sequences being related at a 9 
90%, or higher, level to cultivated organisms (Sievert et al., 2000).  10 
The deep eastern basin of the Mediterranean Sea is one of the world’s most 11 
oligotrophic areas and is characterized by an overall nutrient deficit (Ignatiades 1969). As a 12 
result, only small amounts of organic matter reach the seafloor through the water column, 13 
resulting in low bacterial community growth and abundance (Danovaro 1999). Previous 14 
studies on the composition of microbial communities in these environments have shown that 15 
they are highly diverse, and the estimated total sequence richness has been found to be 16 
comparable to estimates for microorganisms inhabiting terrestrial ecosystems (Polymenakou 17 
et al. 2005; Polymenakou et al. 2009). Thus, these highly oligotrophic environments harbour 18 
a unique prokaryotic diversity, different from that described among other oxic and pristine 19 
marine sediments, and thus they can be considered as ”bacterial hotspots” that deserve further 20 
investigation to assess their biotechnological potential.  21 
For the first time, SeaBiotech was able to launch bioprospecting activities on 22 
organisms from these Mediterranean sources which were led by the Hellenic Centre for 23 
Marine Research (HCMR).  Samples were collected in Santorini volcanic complex (Santorini 24 
caldera including the newly discovered Kallisti lakes, Kolumbo volcano, Aegean Sea, 25 
Greece) and in the deep-sea oxic Ierapetra basin, South Crete. Santorini volcanic complex is a 26 
part of the Hellenic Volcanic Arc characterized by a unique convergent setting and by a 27 
unique enrichment of polymetallic spires in As, Sb, Zn etc. Two major sampling events were 28 
organized by HCMR in September 2013 and in May 2014 in this volcanic complex with the 29 
Research Vessel Aegaeo and the remote operated vehicle of HCMR from which a large 30 
number of water samples (>100), pollymetalic active and inactive gas chimneys (>30 samples 31 
and subsamples) from the submarine Kolumbo volcano and microbial mat samples from 32 
Santorini caldera and Kolumbo volcano (>30) were collected and used for microbial strain 33 
isolation, community characterization and metagenomic libraries construction. In total, 280 34 
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microbial strains were finally isolated from the Kolumbo/Santorini samples for the other 1 
tasks and WPs, belonging to different species mainly within the Bacillales of Firmicutes 2 
phylum and within the Pseudomonadales of Gammaproteobacteria. Several novel species 3 
were also identified whereas additional strains isolated from the Milos sampling event of 4 
May 2013 are available also in MATIS strain collection. In addition a series of 5 
physicochemical parameters (e.g. gas analysis of the active vents, nutrients, organic carbon, 6 
metals, chloropigments etc) were also estimated in order to explain microbiological results 7 
and further evaluate the potential risks of the active submarine volcanoes of the Hellenic arc 8 
(Rizzo et al., 2016). HCMR has created a collection of 280 strains from the extreme 9 
environments of the Hellenic Volcanic arc. 10 
3.1.34.1.3 Coastal sites in Scotland with extreme conditions 11 
The west coast of Scotland and its outer islands provide a wide variety of extreme ecological 12 
niches including rock-pools, which undergo major shifts in osmotic potential and 13 
temperature, unusual niches such as the stratified, anoxic microzone at the head of Loch 14 
Etive, and highly polluted sites on the River Clyde estuary. These sources have not yet been 15 
explored for bioprospecting, but within SeaBioTech examination of the microbial diversity in 16 
these sites were undertaken. SAMS (Scottish Association for Marine Science) has created a 17 
unique collection of strains encompassing of a wide range of taxa including: a range of 18 
heterotrophic eubacteria, cyanobacteria and eukaryotic micro-algae. In total 480 biological 19 
isolates have been identified in the project and processed down the biodiscovery pipeline by 20 
SAMS, with 116 of these being identified by 18S rRNA gene sequence NCBI blast results in 21 
Period 3. Of these 310 biological isolates; were processed down the biodiscovery pipeline. Of 22 
the 310 samples processed, 246 were of bacteria identified in this project by molecular 23 
barcoding (16S rRNA gene) and 64 were algal, with identity confirmed by 18S rRNA gene 24 
sequence NCBI blast results. All the live microorganisms identified are held in the bacterial 25 
and protistan collections at SAMS. All bacterial isolates are held as frozen/ cryopreserved 26 
master stock-cultures at -80oC, with glycerol (5% in medium) as cryoprotectant.  The algal 27 
isolates are maintained by serial transfer and where practicable they are also held as 28 
cryopreserved master-cultures and stored at -196oC in the CCAP Cryostore. 29 
 In addition, MBL has created a collection of 165 strains over 4 sampling sessions 30 
from Culzean bay and Oban. Of those strains which were isolated, the dominant members 31 
were affiliated within the class of Gammaproteobacteria and the phylum of Firmicutes.  32 
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3.1.44.1.4 Microbial symbionts from sponges 1 
Marine sponges often harbour dense and diverse microbial communities, with many of the 2 
microorganisms being specific to sponge hosts. These microbes, which can include bacteria, 3 
archaea and single cell eukaryotes, comprise up to 40% of sponge volume and may have a 4 
profound impact on host biology. For example, photosynthetically fixed carbon from 5 
cyanobacterial symbionts provides >50% of the energy requirements of certain tropical 6 
sponges, while other microorganisms may contribute to host defence via the production of 7 
biologically active metabolites. The latter also hints at the pharmacological potential of 8 
sponge-associated microorganisms. The group of Professor Ute Hentschel at the University 9 
of Wuezburg (UWUERZ) has a long experience in marine sponge microbiology, many of 10 
which have been collected from the Mediterranean Sea (Schmitt et al. 2011). Samples and 11 
background knowledge was made available to SeaBioTech from two collection efforts to the 12 
Greek islands yielded the following biomaterial: 64 unique actinomycetes were isolated from 13 
12 different marine sponge species, which were affiliated to 23 genera representing 8 14 
different suborders based on nearly full-length 16S rRNA gene sequencing ; 4 putatively 15 
novel species belonging to the genera Geodermatophilus, Microlunatus, Rhodococcus, and 16 
Actinomycetospora were identified based on a sequence similarity <98.5% to validly 17 
described 16S rRNA gene sequences; and 13 isolates showed antioxidant, antimicrobial, and 18 
antitrypanosomal activities.    19 
3.1.54.1.5 Existing collections 20 
The marine resources exploited under SeaBioTech also included all culture collections 21 
available from partners. MATIS had amassed large strain collections of extreme organisms 22 
and also recently set up facilities and pipeline for eukaryotic microalgae collection and 23 
analysis. The Culture Collection of Algae and Protozoa (CCAP), located at SAMS, holds a 24 
uniquely diverse range of marine, freshwater and terrestrial protists (algal and protozoan) as 25 
well as prokaryotic cyanobacteria. Additionally, SAMS has collections of marine bacteria 26 
that are not replicated in any accessible Biological Resource Centre. HCMR has an existing 27 
microbial collection from deep sea sediments and from submarine volcanic sites in the 28 
Eastern Mediterranean.   The Natural Products Metabolomics group at the Strathclyde 29 
Institute of Pharmacy and Biomedical Sciences (SIPBS) also has a collection of marine 30 
microbes from the Northern Scottish coastlines of Orkney and Shetland.  These collections 31 
have not been previously investigated for their potential to produce bioactive secondary 32 
metabolites and provided biotechnologically exploitable metabolites within SeaBioTech. 33 
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3.1.64.1.6 Advances in the sampling and collection of extremophiles 1 
From existing collections from different partner institutions, isolates have also been 2 
additionally generated from the following sources: Scottish sponge isolates (~150); Scottish 3 
& Antarctic sediment cores (~100 of which 54 have been processed); and polar Antarctic & 4 
Arctic sediment cores (~150). SeaBioTech partners shared their expertise in the successful 5 
sampling of extremophiles, and developed a common and efficient strategy to optimize the 6 
useful access to marine biodiversity. Targeted scientific and technological tools (ROV based 7 
technology) for deep sea sites and scientific diving for shallow sites for observing and 8 
sampling submarine ecosystems and collecting sponge samples were deployed to explore the 9 
series of diverse habitats described above. MATIS focused on geothermal coastal areas 10 
around Iceland and developed various methods isolating psychrophilic and thermophilic 11 
microbes relevant to the project. Specialized techniques were developed in the project for 12 
accessing rare species in order to increase the overall “phylogenetic depth” of the obtained 13 
strain collection. In addition to direct production of samples through cultivation methods 14 
(described in the next section), 15 
SeaBioTech also employed molecular genetics, particularly a metagenomic sampling 16 
approach vastly increasing its access to relevant DNA from marine samples. The advent of 17 
molecular genetics in the 1970s prompted a major revelation in microbiology (Woese 1987). 18 
A huge pool of microbiota was discovered that had been previously missed because of their 19 
lacks of growth on laboratory media (Rappe & Giovannoni 2003). Several dozens of phyla 20 
have been discovered since then, encoding many novel metabolic functions and pathways 21 
(Achtman & Wagner 2008). Because of the sheer numbers of microorganisms in 22 
environmental samples, the limits of discovery have clearly not yet been reached: in addition 23 
to the 105-106 bacteria per ml seawater, an unimaginable number of microorganisms is 24 
associated with algal and animal surfaces, residing as commensals in the intestines of 25 
animals, or as symbionts in highly specialized organs, such as the cellulose degrading 26 
symbionts of wood-boring bivalves or the symbiotic microbial consortia of marine sponges.  27 
In order to access this largely untapped resource of marine microorganisms, metagenomic 28 
strategies were employed in the project. Metagenomics (or ‘environmental genomics’) 29 
involves the direct extraction of community high-molecular weight DNA from an 30 
environmental sample, and the cloning of the resultant DNA pool (called the ‘metagenome’) 31 
into suitable vectors (Grozanov & Hentschel 2007; Hugenholtz & Tyson 2008; Vieites et al. 32 
2009). The cloning vectors have been designed to hold small, medium or large insert sizes. 33 
These vectors (fosmid, cosmid) are then propagated in surrogate host strains, such as E. coli 34 
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or specialized overexpression strains, such as Streptomyces albus, and others. With the 1 
generation of large libraries consisting of tens to hundreds of thousands of clones, the 2 
genomic complexity of the original microbial community can be maintained. These libraries 3 
were then screened, in what has been termed a “functional metagenomics” approach, for 4 
phenotypic activities and the responsible operon structures are sequence. In doing so, a 5 
number of enzymes (including esterases, lipases, cellulases, amidases, amylases), ribosomal 6 
operons, antibiotics and pigments have been recovered from environmental microbial 7 
communities whose large uncultured fraction would otherwise have been inaccessible 8 
(Lorenz & Eck 2005; Kennedy et al. 2010, 2011). Owing to the environment from which the 9 
enzymes had been isolated, they may have novel properties, such as increased stabilities 10 
under alkaline, acidic, or low or high temperature conditions. Functional metagenomics is 11 
thus a highly promising strategy for the recovery of biotechnologically relevant enzymes 12 
from the marine environment. 13 
Another strategy used by SeaBiotech to tap into the environmental DNA pool is by 14 
“sequence-driven metagenomics”. This approach has been undertaken by Venter and 15 
colleagues to yield a global genomic inventory of the oceans (Rusch et al. 2007). Other 16 
studies have employed sequence-driven metagenomics for example, to characterize the 17 
genomic repertoire of the microbial consortia of marine sponges (Fieseler et al. 2007; 18 
Thomas et al. 2011), of whale fall carcasses (Tringe et al. 2005) and the deep sea (Eloe et al. 19 
2011). The main outcomes of sequence-driven metagenomics are predictions on the 20 
metabolic repertoire of a given sample, to delineate metabolic pathways and to assess the 21 
potential of an environmental sample to perform specific, sought-after tasks. Single cell 22 
genomics based on whole genome amplification (WGA) is an emerging technology in the 23 
field of environmental microbiology, which is complementary to metagenomics (Hutchison 24 
& Venter, 2006; Ishoey et al. 2008). Owing to the experimentation and manipulation of 25 
single microbial cells, this technique allows promising genomic insights into complex 26 
environmental microbial consortia whose members are frequently resistant to cultivation 27 
(Siegl et al. 2011). Importantly, functional assignments of primary and secondary metabolism 28 
genes to specific bacterial genes of known phylogenetic identity are possible (Siegl & 29 
Hentschel 2010). Metagenomics and other –omics methods have opened new avenues for the 30 
sustainable production of marine enzymes/drugs that would otherwise be inaccessible by 31 
conventional microbiology techniques. By merging the scientific disciplines of molecular 32 
genetics, microbiology, chemistry and biochemistry, the promise that marine microorganisms 33 
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hold for industry is becoming a manageable task. The advent of massive parallel DNA 1 
sequencing techniques has set the stage for the next level of genomic and 2 
metagenomic bioprospecting. This methodology provided the means for isolating genes 3 
directly from environmental DNA without cloning. In the SeaBioTech consortium, high 4 
throughput pyro-sequencing technology from Roche (the 454 genome sequencing platform) 5 
was the key instrument for metagenomics mining which was complemented upon demand by 6 
other sequencing technologies (e.g., Illumina). Importantly, sequence read lengths on the 7 
average of 700 bases were obtained with the 454 FLXplus platform, which resulted in higher 8 
numbers of informative sequences. The advantages of sequence-based metagenomics are 9 
many: this gave enzyme leads at least of an order of magnitude greater than other currently 10 
used screening techniques. A large number of genes were predicted to be detected that do not 11 
turn up using activity screening due to expression problems or the use of suboptimal 12 
substrates. And, as the genomic/metagenomic enzyme/gene discovery methodology is 13 
sequence-based, gene redundancy was eliminated very early in the process, which minimized 14 
the downstream analysis work. This was especially important for large-scale metagenomic 15 
sequencing projects as the sequence capture method reduced the need for as high coverage of 16 
sequencing for complete gene retrieval. The SeaBioTech methodology took the metagenomic 17 
mining out of the domain of large specialized companies and brought it into the field of small 18 
companies, universities and institutions. Hence, one of the most important contributions of 19 
SeaBioTech project was “affordable metagenomics”.  Samples for metagenome libraries 20 
were made available from the project which, included strains from Yngingarlindir water 21 
samples in Iceland, microbial mats and sponges from Milos Island and Santorini volcanic 22 
complex in Greece; strains from Kallisti lakes water samples, strains collected from Kolumbo 23 
microbial mats covering the ocean floor and the polymetallic chimneys.  24 
3.1.74.1.7 Metagenomic bioprospecting 25 
UWUERZ employed a metagenomic bioprospecting approach to unravel the differences in 26 
the functional gene repertoire between three Mediterranean sponge species, Petrosia 27 
ficiformis, Sarcotragus foetidus, Aplysina aerophoba and seawater, collected during a SBT 28 
sampling expedition (WP2). Microbial diversities were compared to those of other sponges 29 
within an EMP global sponge microbiome effort and contributed to the largest microbiology 30 
survey in sponges so far conducted (Thomas et al., 2016). 31 
With respect to gene function, different signatures were observed between sponge and 32 
seawater metagenomes with regard to microbial community composition, GC content, and 33 
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estimated bacterial genome size. The analysis showed further a pronounced repertoire for 1 
defense systems in sponge metagenomes. Specifically, Clustered Regularly Interspaced Short 2 
Palindromic Repeats (CRISPR), restriction modification, DNA phosphorothioation and phage 3 
growth limitation systems were enriched in sponge metagenomes (Horn et al., Frontiers in 4 
Microbiol, under review). These data suggest that the “defensosome” is an important 5 
functional trait for an existence within sponges that requires mechanisms to defend against 6 
foreign DNA from microorganisms and viruses.  7 
With respect to secondary metabolism, the most abundant marker genes in the 8 
microbial metagenomes belonged to the groups of saccharides, bacteriocins, terpenes and 9 
fatty acids. Other indicator genes of secondary metabolism – linaridin, lantipeptides, ectoines, 10 
phosphonates, proteusin, polyketide synthases, nucleosides, microcins, siderophore or 11 
homoserine lactones - were found only in low copy numbers. Interestingly, while 12 
siderophores and homoserine lactone hits were only identified in seawater, lantipeptides, 13 
linaridines, and Type I Polyketide synthases were exclusively found in the sponge 14 
metagenomes. A total of 120 Type I PKS genes in the three sponge metagenomes were 15 
further identified. Phylogenetic analysis assigned the majority (109/120) to the symbiont 16 
ubiquitous supA-type PKS group. Most similar sequences from the sponge metagenomes 17 
were derived from bacterial symbionts of other sponge species. Most of the polyketide 18 
synthases in the supA clade of the tree resulted in a hit to epothilone with low to moderate 19 
sequence identities. Despite the variance of possible products in the FAS-like PKS clade, the 20 
order of the genes surrounding the polyketide synthase was highly conserved.   21 
MATIS sequenced 34 novel bacterial strains from geothermal intertidal areas in 22 
Iceland, assembled and annotated for bioprospecting. An additional 4 strains that had been 23 
sequenced before SeaBioTech were also annotated at the beginning of SeaBioTech to allow 24 
bioprospecting to start. Of the 38 sequenced strains, 13 (34%) belong to the α-25 
Proteobacteria, 10 (26%) to Bacteroidetes, 7 (18%) to Firmicutes, 6 (16%) to γ-26 
Proteobacteria and one strain each to Actinobacteria and Chloroflexi. All strains are 27 
thermophiles or moderate thermophiles. 28 
HCMR generated 2 metagenomic libraries from the Kallisti lakes in Santorini caldera 29 
characterized by high concentrations of metals and differences in pH, temperature and 30 
nutrient concentrations. HCMR also generated another 3 metagenomic libraries from a 31 
polymetallic spire located within the submarine Kolumbo volcano of the Hellenic Volcanic 32 
Arc. Each library has been constructed from different microbial mat layers of the spire 33 
characterized by differences in metal concentrations.  34 
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3.1.84.1.8 Genome mining of bacterial isolates 1 
UWUERZ provided draft genomes of 3 selected actinomycetes (Horn et al., 2015). 2 
Metabolomic analysis in WP5 has shown the chemical richness of the sponge-associated 3 
actinomycetes Streptomyces sp. SBT349, Nonomureae sp. SBT364, and Nocardiopsis sp. 4 
SBT366 that had been isolated from sponges during a SBT sampling expedition. The 5 
genomes of these three actinomycetes were subsequently sequenced and draft genomes were 6 
mined using antiSMASH and NapDos.  Streptomyces sp. SBT349 displayed the most diverse 7 
read-out. A total of 108 potential secondary metabolite gene clusters were predicted, 8 
encoding for 23 type I polyketide synthases (PKS), 11 non-ribosomal peptide synthetases 9 
(NRPSs), 2 terpenes, 21 saccharides, 3 siderophores, 3 lantipeptides, 1 butyrolacetone, 1 10 
bacteriocin, 1 phenazine, 1 ladderane, and 1 linaridin, as well as 26 unidentified putative 11 
clusters. Furthermore, NaPDoS predicted the presence of natural products such as nystatin, 12 
rapamycin, rifamycin, epothilone, and tetronomycin.  For Nonomureae sp. SBT364, NaPDoS 13 
predicted the presence gene clusters encoding for rifamycin, avermectin, avilamycin, 14 
concanamycin, and tetronomycin. Thirdly, for Nocardiopsis sp. SBT366, gene clusters 15 
encoding for pikromycin, alnumycin, amphotericin, and mycinamicin were predicted. In 16 
summary, UWUERZ efforts provided new insights into the genomic underpinnings of 17 
actinomycete secondary metabolism, which may deliver novel chemical scaffolds with 18 
interesting biological activities for the drug discovery pipeline.  19 
An extremely high level of novelty was presented by this panel of novel strains. 20 
Based on 16S rRNA gene sequencing of the 38 genomes, 19 strains (50%) shared less than 21 
94% similarity with their closest relative and are therefore considered novel species and 22 
novel genera. 10 (26%) shared between 94% and 97% similarity and are considered novel 23 
species and the remaining 9 strains (24%) shared more than 97% similarity with their closest 24 
relative. Strain MAT4553, which has 90% similarity with its closest relative Rhodothermus 25 
marinus (16S rRNA gene) was selected for further characterisation carried out by MATIS. It 26 
has been assigned the species name Rubrimicrobum thermolitorum and characterisation is 27 
still currently ongoing.  28 
All 38 strains were annotated using subsystem annotation servers (RAST and MG-29 
RAST), the genomes mined for novel genes of interest and analysed by antiSMASH for 30 
putative secondary metabolite gene clusters. A total of 2432 putative gene clusters were 31 
predicted, including 20 Non-Ribosomal Peptide Synthetase clusters and a total of 30 32 
Polyketide Synthase clusters of Types I, II or III.  A total of 64 genes encoding novel 33 
enzymes for applications in marine macroalgal biorefineries were identified and delivered for 34 
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cloning, expression and functional analysis in WP6 including,  51 carbohydrate active 1 
enzymes (CAE) 3 enzymes (oxidases) putatively active on polyphenols, 5 alcohol 2 
dehydrogenases, a sulfatase and 4 proteases. A total of 58 genes encoding novel enzymes 3 
including thioesterase, cyclic peptide related genes, and (3) lysine exporters ,  for application 4 
in synthesis of added value chemical and pharmaceutical were identified and delivered to 5 
IGZ for, cloning , expression  in their proprietary  inABLE®  system and  for further analysis 6 
and selection in WP6. 7 
SAMS undertook whole genome sequencing of five bacterial strains and delivered a 8 
total of four draft whole bacterial genomes. The fifth bacterial genome was to be of the 9 
filamentous cyanobacterium, Nodularia harveyana CCAP 1452/2. This was advanced to the 10 
point of achieving an axenic culture (WP2) and development of a useable DNA extraction 11 
protocol based on mechanical tissue disruption without pre-digestion of the cell walls using 12 
the lysozyme, and purification using the quarternary ammonium detergent cetyl trimethyl 13 
ammonium bromide. However, significant quantities of polysaccharide were found to 14 
contaminate the DNA preparations, and refinements to the protocols were not successful in 15 
removing this. This meant the genome sequencing centre were unable to prepare the DNA 16 
library required for PacBio RSII genome sequencing. 17 
All genome data was mined for enzymatic and secondary metabolite potential. In 18 
terms of carbohydrate active enzymes and xenobiotic degradation potential, Colwellia and 19 
Rhodococcus (SBT017), respectively, had the greatest potential of the four organisms. The 20 
Colwellia genome data will serve as an important resource for the scaling up and 21 
commercialisation of the gel-forming biopolymer this organism produces (WP7) during a 22 
PhD studentship working in conjunction with the multinational company, Unilever. The 23 
Rhodococcus genome is undergoing further analysis to link the secondary metabolite clusters 24 
identified with the metabolome of this organism fermented under different conditions (WP5 25 
and WP7).  26 
The Acidobacteria (Holophagales) genome showed an especially high number of 27 
novel secondary metabolite gene clusters belonging to the non-ribosomal peptide synthetase 28 
(NRPS) and polyketide synthase (PKS) classes.  Metabolomic analysis (WP5) did not 29 
identify production any secondary metabolites putatively linked with these cluster, nor was 30 
any bioactivity identified (WP3). The lack of novel secondary metabolite production by the 31 
Acidobacteria is hypothesized to be a failure to induce the many cryptic secondary metabolite 32 
operons. This hypothesis is given some support by the observation that many signal 33 
transduction systems were found within or immediately adjacent to these clusters. This 34 
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suggests that these clusters are tightly regulated and are part of a signal transduction relay 1 
activated by specific signalling molecules or environmental stressors. In conclusion, this 2 
organism holds significant potential for secondary metabolite production. But, to achieve this 3 
though, further funding is required try to activate the cryptic secondary metabolite clusters, as 4 
well as continue to isolate and genome sequence new marine Acidobacteria from the 5 
environment. 6 
Vibrio splendidus SBT027 produced a range of bisindoles, including the compound 7 
turbomycin. Several putative genes were identified that may be linked with turbomycin 8 
production. First, the biosynthetic pathway for the assumed precursor, L-tryptophan, was 9 
identified. Second, the enzyme 4-hydroxyphenylpyruvate dioxygenase had previously been 10 
identified as a part of turbomycin production, and this was identified in this genome. Third, 11 
inosine-5’-monophosphate dehydrogenase has been shown to be important in bisindole 12 
production previously, and this gene was also identified. However, as these genes are not 13 
organized in an apparent gene cluster, it is uncertain how these genes are involved in 14 
Turbomycin production by this Vibrio. Moreover, the above genes are all highly conserved 15 
and syntenic in all other Vibrio splendidus genome sequenced isolates. This suggests either, 16 
that all V. splendidus are capable of Turbomycin production, or that the main pathway for 17 
bisindole and/or Turbomycin production in V. splendidus SBT027 has not been correctly 18 
identified. Clearly, further work is required to identify this pathway.  19 
The second aspect of the ‘quality of marine resources’ challenge is cultivation. 20 
Traditional techniques are often inadequate for accessing the microbial diversity of any given 21 
habitat. Studies from many extreme areas including MATIS’ current and ongoing work in 22 
Iceland have demonstrated that cultivation of microorganisms living under extreme 23 
conditions is particularly difficult. The main reason for the low ratio of presently cultivatable 24 
microbial species is that their isolation takes place under both space and time limited by 25 
laboratory conditions. Other factors that explain the low ratio of cultivated species include 26 
unknown conditional or nutritional requirements or other important chemical components 27 
supplied to the species in their natural environment and missing in laboratory media. There 28 
could also be requirements for interdependent co-cultivation of two or more different species. 29 
A nutritionally rich laboratory medium is not a natural medium for many environmental 30 
microbes. Copiotrophic organisms therefore gain a competitive edge and out-compete 31 
oligotrophic species, although they may be more abundant in the habitat. Furthermore, rich 32 
medium may be growth inhibiting for oligotrophic species. Classical resource-competition 33 
theory maintains that highest diversity occurs when many resources are limiting. In addition, 34 
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high species diversity can be maintained by periodic disturbance or by environmental 1 
fluctuations (i.e., nutrients, pH and temperature) (Buckling et al. 2000). Laboratory 2 
conditions that allow microbes to grow to high density in a short time are "unnatural" for 3 
many natural microorganisms that normally grow slowly, at very low and steady state 4 
concentrations of nutrients (Fry 1990). Re-creation of "nature-like" or natural, low nutrient or 5 
oligotrophic conditions have been attempted in a few cases but can only be done on a small 6 
scale and with great effort (Huber et al. 1998). Growing many oligotrophs in the laboratory 7 
on a large enough scale would be practically impossible. Different modifications of the 8 
enrichment concept have been developed in order to culture more novel organisms. These 9 
included serial-dilutions or pre-treatment of the sample. The purpose is to kill or dilute out 10 
numerically less numerous copiotrophic fast growing organisms in the sample before 11 
inoculating the enrichment medium (Grosskopf et al. 1998; Santegoeds 1996). Still another 12 
attempt towards"nature-like"enrichments is the technique of in situ enrichment or substrate 13 
colonization, which has been used in several environments. In situ enrichment is based on the 14 
principle of introducing one or few new factors into an existing “natural” environment. 15 
Techniques of in situ enrichments have been of interest to microbiologists ever since bacteria 16 
were found to colonize microscope slides submerged in aquatic environments (ZoBell et al. 17 
1943; ZoBell & Anderson 1936). Such techniques have been used in hot springs to obtain 18 
specific groups of microorganism, by using specific substrates such as cellulose. These 19 
techniques may be of special value for isolating or enriching species utilizing polysaccharides 20 
unique to the marine organism found in coastal areas. In the SeaBioTech project, the 21 
consortium developed selective enrichment methods, and serial dilutions for accessing rarer 22 
and potentially more interesting members of bacterial and protistan communities. The 23 
consortium was able to increase the overall diversity and phylogenetic depth of obtained 24 
strain collection for consequent screening for bioactive microbial metabolites and thus 25 
maximized the likelihood of obtaining novel bioactive lead-compounds. Enrichment methods 26 
were developed targeted towards certain metabolic types belonging to heterotrophic 27 
actinomycetes, thermophilic bacteria, marine and extremophilic cyanobacteria and rare 28 
coastal psychrophilic heterotrophs by using various cultivation methods and enrichment 29 
procedures. Special substrates such as complex recalcitrant polysaccharides or single carbon 30 
sources of predetermined type and structures were used often in conjunction with group 31 
specific inhibitory substances. 32 
A third aspect of the ‘quality of marine resources’ challenge is accurate identification. 33 
Sampling of marine microbes from a range of environments was explored by 16S rRNA 34 
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and/or other candidate genes in order to assess the potential of the communities for industrial 1 
purposes and redirect new sampling. By 16S rRNA gene sequencing followed by 2 
phylogenetic tree construction analyses, the taxonomic identity of the bacterial isolates was 3 
determined. Colony lysates were amplified by PCR (Polymerase chain reaction) using the 4 
universal bacterial primers 27f and 1492r while PCR products were sequenced directly. DNA 5 
extraction protocols (i.e. for cells with hardy cell walls) and PCR conditions were optimized 6 
where necessary. Full 16S rRNA sequences of selected candidates were provided and 7 
phylogenetically isolated. Strain descriptions of novel species or genera were also 8 
undertaken. The genomic potential of bacterial isolates were assessed by PCR screening for 9 
genes indicative of secondary metabolism such as, polyketide synthases, non-ribosomally 10 
encoded peptide synthetases, halogenases and other genes of relevance for secondary 11 
metabolism. Likewise, metagenomics approaches were employed to assess the genomic 12 
potential of previously uncultivated marine microbial consortia. Biotechnologically relevant 13 
gene clusters were cloned into cosmid/fosmid vectors, sequenced and analysed with 14 
bioinformatic prediction tools. Full genome sequencing was performed for isolates of special 15 
interest using deep sequencing (454/Ilumina). 16 
3.24.2 Challenge 2: Improvement of technical aspects of the 17 
biodiscovery pipeline 18 
Once samples from marine bioresources were obtained, they were explored for the presence 19 
of useful bioactivities. When activity was found, the component responsible was identified 20 
and characterised. The SeaBioTech project developed systems to enhance the efficiency and 21 
effectiveness of both bioactivity detection and compound isolation and characterisation. 22 
SeaBioTech focused on discovering useful marine components with enzyme activity, as 23 
biopolymers or with drug-like properties. The enzyme activities were predicted from analysis 24 
of metagenomic data followed by functional expression (Ferrer et al, 2016). Biopolymers 25 
were identified, quantified, as well as extracted and isolated. Development of biopolymers 26 
included progressive pharmaceutical screening as well as investigating the potential role of 27 
(isolated) algal endophytes in improving polymer and cultivated macroalgae resources, which 28 
are a well-established, but not fully developed, source of natural polymers. The next sections 29 
discussed the present state of ‘drug hunting’ and how SeaBioTech enhanced this process 30 
through improvements in screening and natural product chemistry. 31 
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3.2.14.2.1 Bioactivity screening 1 
The biodiscovery pipelines focused on the following categories: polymers, enzymes and 2 
small molecules used for drug discovery, functional foods or cosmetics. Drug discovery 3 
programmes seeking new bioactive compounds are driven by the existence of unmet 4 
therapeutic needs. In recent decades, advances in the understanding of the molecular basis of 5 
diseases and sequencing of the human genome and of pathogenic hosts have expanded the 6 
number of plausible therapeutic targets for the development of innovative drugs (Hopkins & 7 
Groom 2002; Russ & Lampel 2005). Therefore, a wealth of new technologies and paradigms 8 
has been established since the mid-1990s, with the initial expectation of generating novel 9 
drugs in a greater number and in a shorter time. Among others, cardinal roles were played by 10 
molecular biology, combinatorial chemistry and high-throughput screening (Drews 2000; 11 
Leland et al. 2003). First, genetic manipulation of expression host cells using molecular 12 
biology allowed the development of target based functional assays, in place of the traditional 13 
phenotypic systems (Drews 2000; Leland et al. 2003). In parallel, improvements in organic 14 
synthesis through combinatorial chemistry exponentially expanded the size of small-molecule 15 
compound collections (Chabal 1995). Consequently, natural products (which had been the 16 
basis of most previous drug discovery programmes) were progressively neglected. To 17 
confront the massive effort required to test the large number of newly identified molecular 18 
targets with huge chemical libraries, multiple areas of biology, chemistry, engineering, 19 
robotics, statistics and information technology were integrated to create high throughput 20 
screening (HTS). Hence, HTS has been established in large pharmaceutical companies as the 21 
technological platform able to screen compound collections containing over 1,000,000 22 
molecules on biochemical and cellular assays in an automated manner and miniaturized 23 
format (Hüser et al. 2006; Carettoni & Verwaerde 2010). Subsequently, prominent academic 24 
institutions decided to exploit the potential of these technological advancements through 25 
initiatives to assemble centralized compound collections and screening facilities with the aim 26 
of identifying molecular probes with prospective applications in basic and applied biomedical 27 
research (Verkman 2004). 28 
Although this pioneering approach to drug discovery has been successful in delivering 29 
innovative clinical candidates and marketed drugs (Macarron 2006; Macarron et al. 2011), it 30 
is undoubtedly true that the original expectations in terms of overall performance are far from 31 
being met and unlikely to be achievable. Rather, the increasing costs associated with the 32 
infrastructural and technological investments have contributed (within a framework of 33 
tackling more challenging diseases, higher scientific risks, increasing safety requirements and 34 
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larger clinical trials) to the so-called “productivity gap” in pharmaceutical R&D, which has 1 
been posing major issues for the sustainability of drug development in the private and public 2 
sectors (Pammolli et al. 2011). Therefore, while the main technological improvements are 3 
still considered essential cornerstones for R&D, the basic paradigms of the process are 4 
currently under debate (Macarron 2006; Leeson and Springthorpe 2007; Harvey 2008; Mayr 5 
& Bojanic 2009). In particular, phenotypic screenings have been currently reconsidered as 6 
valid options along with target-based molecular assays, particularly for certain therapeutic 7 
areas (e.g. pathogenic infections, cancer and others) (Payne et al. 2007; Mayr & Bojanic 8 
2009). Moreover, emphasis has been given to highly validated targets, i.e. targets whose 9 
activity has been proven to be modulated by a chemical compound and with a direct 10 
causative link to the disease to be addressed. Therefore, highly innovative but poorly 11 
characterized targets were deprioritized (Gashaw et al. 2011). More recently, attention has 12 
been focused on the quality of the compounds in the chemical libraries, rather than on the 13 
number of compounds. In fact, retrospective analysis unequivocally clarified that early 14 
combinatorial chemistry produced large libraries with very limited diversity (Macarron 2006; 15 
Macarron et al. 2011). At present, investments in compound collections are not aimed at a 16 
numerical size increase, but at ensuring a constant stream of new chemotypes, meaning that 17 
natural products and mimetic derivatives are back into consideration (Harvey 2008; Macarron 18 
et al. 2011). This implies that drug discovery has to face well-known problems inherent to 19 
natural products, like supply at screening scale, purification, identification and structural 20 
complexity (Grabowski & Schneider, 2007; Ganesan, 2008). However, technical solutions 21 
have been rapidly developing to overcome these bottlenecks and in order to gain access to the 22 
potential of this valuable source of chemical diversity (Kennedy 2008; Rishton 23 
2008; Koehn 2008). Under this developing scenario, the SeaBioTech consortium integrated 24 
some of the most advanced technological applications with state of the art expertise in drug 25 
discovery research to identify bioactive compounds from libraries of marine origin. To 26 
increase the chances of a positive outcome of the screening campaigns, the assay types 27 
applied in SeaBioTech comprised a wide array of target-based and phenotypic assays. 28 
Some were configured in HTS-suitable formats to ensure a high processivity of large 29 
compound collections and of hit profiling; some will be performed as low-throughput assays 30 
to achieve a high level of information directly from primary screening (e.g., assays against 31 
sea lice affecting farmed salmon). Most importantly, all assays within SeaBioTech 32 
represented functional assays designed to provide unambiguous responses concerning their 33 
relevance for biomedical and biotechnological applications (e.g., isogenic X-MAN human 34 
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disease models from HDL). Having no pre-existing knowledge on the bioactivities present in 1 
the extract/compound collections obtained from underexplored marine sources, SeaBioTech 2 
members screened a very wide set of assays with relevance to diverse therapeutic areas, 3 
including cancer (AXXAM; HDL; MATIS), bacterial, viral and parasitic infections (SIPBS; 4 
AXXAM; UWUERZ), inflammation (SIPBS; MATIS), cardiovascular diseases (AXXAM; 5 
MATIS), metabolic disorders (SIPBS) and pain (AXXAM). Besides human health, 6 
SeaBioTech sought bioactive compounds to treat parasitic infections in aquaculture 7 
(PHARMAQ) and for food and cosmetics industry (MATIS). It is worth noting that discovery 8 
programmes in these fields are encouraged by the successful outcome of research projects 9 
using compounds of marine source, which have recently yielded molecular probes, pre-10 
clinical candidates and therapeutic drugs in several clinical areas, including cancer 11 
(Napolitano et al. 2009; Dumontet and Jordan 2010; Galeano et al. 2011), bacterial, viral and 12 
parasitic infections (Mayer et al. 2011), inflammation (Folmer at al. 2010; Mayer et al. 13 
2011), Alzheimer’s disease (Williams et al. 2010), and pain (Teichert & Olivera 2010; Mayer 14 
et al. 2011). 15 
Since the final aim of SeaBioTech was the exploitation of the value of the new 16 
compounds, participants did not limit their investigation to the identification of hit 17 
compounds through primary screening, but also employed their competencies in more 18 
advanced stages of the drug discovery process, including studies on selectivity, mechanism-19 
of-action, early toxicology and proof-of-principle in animal models. This guaranteed that the 20 
outcome of the bioactivity assessments were not just be compounds that ‘hit’ particular 21 
targets, but an activity profile of a bioactive substance and its drug-like properties. Such 22 
compounds represented potential development candidates, a critical step towards new 23 
medicines. 24 
The organisational aspects of SeaBiotech also provided progress beyond what is 25 
normally achieved in drug discovery programmes in individual SMEs or in academic 26 
institutes. For SMEs, the successful outcome of large-scale drug discovery projects entails on 27 
extensive collaborations and partnership with public academic institutions. On the other side, 28 
access to advanced technological platforms, cost-sustainable exploitation of the results and 29 
interrelation between specific expertises, knowledge and competences were considered 30 
essential prerequisites to identify and progress novel molecular entities for biotechnological 31 
and biomedical applications. Hence, SeaBioTech was structured to promote and implement 32 
synergistic collaboration at two levels. First, extracts and compounds of marine origin 33 
collected and isolated by public research institutes will be made accessible to private 34 
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companies, which in turn will make available their technological platforms and market 1 
oriented approach to develop innovative products for human health and life sciences. In 2 
addition, SeaBioTech represented a valuable opportunity to synergistically link the public and 3 
the private sectors, offering the possibility to progress within an integrated partnership and 4 
providing common objectives through mutual connections. 5 
Second, SeaBioTech inherently enhanced the collaboration among different SMEs 6 
contributing at different stages of the project (identification of hit compounds, hit-to-lead 7 
phase, characterization of lead compounds), in order to define the chemical and 8 
pharmacological properties of the products. Thus, participation in SeaBioTech epitomised a 9 
valid opportunity for SMEs to establish collaborative partnerships with companies with 10 
contiguous expertise and complementary technologies. In parallel, the strategy adopted in 11 
SeaBioTech for bioactivity detection embodied an impressive improvement in terms of 12 
potential exploitation of the chemical diversity of the marine compound collections. Indeed, 13 
libraries of marine origin were subjected to screening campaigns against a panel of more than 14 
20 assays covering over 10 different therapeutic areas or biotechnological applications. This 15 
approach increased the probability that bioactive compounds are retrieved as positive hits, 16 
thus predicting a superior success rate compared to traditional screening on a few assays. In 17 
practice, the adopted strategy places SMEs and research institutes within 18 
The screening method in SeaBioTech closely resembled a large pharmaceutical 19 
company, in which a proprietary compound collection was routinely screened against a series 20 
of disease-relevant assays. However, in SeaBioTech, costs and risks are shared among 21 
different participants, making the overall process more sustainable. In addition, as the 22 
consortium has access to an underexplored chemical diversity and the project focused also on 23 
products for aquaculture, food industry and cosmetics, in which a lower attrition rate is 24 
usually experienced, it then gave a remarkably high productivity for SeaBioTech. The central 25 
goal of the entire SeaBioTech consortium was the isolation and pharmacological 26 
characterization of novel lead candidates of marine origin. This goal was achieved through an 27 
integrated effort between WP2-WP5 with the six members of WP3 (SIPBS, AXXAM, HDL, 28 
PHARMAQ, UWUERZ, MATIS), who have made available comprehensively an array of 41 29 
functional assays with relevance to 12 therapeutic and life science indications. The screening 30 
process and the bioactivity-assisted dereplication of crude extracts and fractions have led to 31 
the isolation and characterization of 35 pure compounds with promising therapeutic 32 
properties. Notable examples are the followings: (1) SBT0345 from Streptomyces sp. was 33 
fractionated by UWUERZ to yield three novel natural products, namely strepthonium A, 34 
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ageloline A and strepoxazine A. Strepthonium A inhibited the production of Shiga toxin 1 
produced by enterohemorrhagic E. coli at a concentration of 80 µM, without interfering with 2 
the bacterial growth (Cheng et al, 2016a). Ageloline A exhibited antioxidant activity and 3 
inhibited the inclusion of Chlamydia trachomatis with an IC50 value of 9.54 ± 0.36 µM 4 
without cytotoxicity towards human kidney 2 cells (Cheng et al, 2016b). Strepoxazine A 5 
displayed antiproliferative property towards human promyelocytic HL-60 cells with an IC50 6 
value of 16µg/mL (Cheng et al, 2016c). Moreover, SBT0345 from Streptomyces sp. was 7 
yielded also the known compound phencomycin, which displayed cytotoxicity against colon 8 
cancer cell line SW48 at 30 µg/mL, and tubermycin B, which showed cytotoxicity against 9 
colon cancer cell lines DLD-1 and HCT116 at 30µg/mL. (2) SBT0348 from Streptomyces sp. 10 
was fractionated by UWUERZ to yield one novel compound, petrocidin A, exhibiting 11 
significant cytotoxicity towards the human promyelocytic HL-60 and the human colon 12 
adenocarcinoma HT-29 cell lines, with IC50 values of 3.9 and 5.3 µg/mL, respectively. (3) 13 
SBT0961 from Polysiphonia lanosa yielded three fractions, which were identified by HDL as 14 
active and selective for rapidly dividing cancer cells, with anti-proliferative properties 15 
strongly correlated with the induction of cell death via apoptosis. (4) MATIS identified from 16 
microorganisms collected from the Icelandic coastline 11 hits displaying high anti-oxidant 17 
activity, 9 hits that inhibited cell viability of breast cancer cell line and 13 hits that inhibited 18 
viability of intestine cancer cell line. (5) SIPBS isolated 13-methyltetradecanoic acid 19 
(SBT2309) from Muricauda ruestringensis, a compound with activity against PTP1B, a 20 
target to treat diabetes and metabolic syndrome. Remarkably, SIPBS isolated the same 21 
compound showing comparable activity against PTP1B at the end of an independent 22 
bioactivity-assisted screening campaign from extracts of another microorganism, 23 
Algoriphagus marincola. (6) SIPBS isolated a series of structurally related fatty acids from 24 
extracts of Algoriphagus marincola, which showed activity against PTP1B and allowed the 25 
definition of a preliminary structure-activity relationship on the basis of the relative potency. 26 
Remarkably, AXXAM isolated with an independent screening campaign for inhibitors of 27 
endothelial lipase, a validated target for atherosclerosis, a series of fatty acids derived from 28 
Algoriphagus marincola partially overlapping with the hits showing activity against PTP1B 29 
at SIPBS. This finding appears consistent with the targeted enzyme EL, which 30 
physiologically releases fatty acids from phospholipids in HDL particles. (7) SBT1997, a 31 
pure compound isolated by SIPBS from Polysiphonia lanosa as active against α-glucosidase, 32 
was identified as a known compound termed lanosol. Lanosol was documented in literature 33 
as an α-glucosidase inhibitor. (8) A series of bromophenyl homologous compounds have 34 
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been identified by PHARMAQ from Polysiphonia lanosa extracts and fractions having a 1 
potent parasiticidal activity against Lepeophtheirus salmonis, a major threat for farmed 2 
salmon in aquaculture. 3 
3.2.24.2.2 Metabolomics approach - Improving isolation and identification of target 4 
compounds 5 
SeaBioTech used the state of the art approaches to isolation of bioactive compounds from 6 
extracts and microbial broths coupled with appropriate NMR (nuclear magnetic resonance) 7 
spectroscopy and mass spectrometry to elucidate chemical structures. Moreover, SeaBioTech 8 
pioneered the use of metabolomics as a new means to guide strain selection and the isolation 9 
of compounds (MacIntyre et al 2014; Cheng et al, 2015), as well as to help improve the 10 
productivity of downstream fermentation methods. Metabolomics is relatively a new field of 11 
‘omics’, adopting to the system biology approach, with the goal of qualitatively and 12 
quantitatively analysing all metabolites contained in an organism at a specific time and under 13 
specific conditions. The metabolome is the complete set of small molecules found in a cell, 14 
tissue or organism at a certain point in time. Metabolomics is considered as the most 15 
functional approach in monitoring gene function and identifying the biochemical status of an 16 
organism (Yuliana et al. 2011). Metabolomics was utilised to confirm the results of the 17 
presence of biosynthetic gene clusters involved in the production of the biologically active 18 
components. This was accomplished with bioactive strains which, included the anti-19 
mycobacterial Vibrio splendidus SBT-027  (MacIntyre et al, unpublished data) and 20 
Rhodococcus sp. SBT-017 found to be active against metabolic diseases (Hislop et al, 21 
unpublished data). Metabolomics in combination with genomics enhanced the production of 22 
important secondary metabolites which is one of the expressed phenotype in a living 23 
organism. Literature has shown that gene clusters are involved in every step of a biosynthetic 24 
pathway as in the production of biologically active polyketides (Moldenhauer et al 2007). 25 
With genomics, gene clusters can be manipulated to control a biosynthetic pathway. The 26 
procedure of employing metabolomics together with genomics to optimise a biosynthetic 27 
pathway to selectively produce biologically active secondary metabolites was explored 28 
during the project’s lifetime. To identify and quantify the metabolites in natural product 29 
extracts is a massive job (Ebada, et al; 2008, Kjer et al; 2010). This is due to the fact that 30 
secondary metabolites have diverse atomic arrangements which results in variations in 31 
chemical and physical properties. They can also be found in wide range of concentrations. 32 
Reliable, robust, selective and high resolution analytical methods are therefore required in 33 
identifying and quantifying multiple chemical groups of natural products. Mass spectrometry 34 
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and NMR spectroscopy were the complementary analytical methods and were commonly 1 
employed in tandem as metabolomics tools. Mass spectrometry is sensitive even at 2 
femtogram levels but may not be reproducible between instrument types and ionization 3 
capability of the metabolites. While NMR data is reproducible, it may not be sensitive 4 
enough to detect metabolites at lower concentrations. Efficient high-throughput gradient flash 5 
and/or medium pressure chromatography, where gram quantities of a microbial extract can be 6 
loaded in a column, will be employed to isolate the bioactive natural products from microbial 7 
extracts. High-throughput gradient medium pressure chromatography is capable of delivering 8 
reproducible isolation schemes with high product yield, which is optimum in the purification 9 
of marine microbial extracts obtained from multiple batches and has great advantage over 10 
conventional column chromatography (Ebada, et al; 2008, Kjer et al; 2010). Structure 11 
elucidation was accomplished utilising pulse field gradient 2D NMR that would be able to 12 
provide high resolution data to determine the structure of complex molecules with multiple 13 
chiral centres as well higher molecular weight peptides and oligosaccharides (Murata et al. 14 
2006). 15 
Metabolomics provided statistical and computational tools to this standard approach of rapid 16 
HPLC (high-performance liquid chromatography) fractionation, which identified the active 17 
entities at an earlier stage (Abdelsohmen et al 2014, Cheng et al 2015). The goal of HPLC 18 
fractionation is to get to higher purity of active components which, however, is not 19 
achievable in the initial chromatographic isolation work. With metabolomics tools, it will be 20 
possible to pinpoint the active components at the first fractionation step as well as identify the 21 
functional groups involve in the bioactivity which would be present in a series of fractions as 22 
implied by the bioactivity screening results. This can be chemometrically achieved by such 23 
metabolomic/PCA approaches (principal component analysis) as shown in an example 24 
presented in figure 3. The use of metabolomics aided in prioritising the fractions that will go 25 
further for purification work, which should save time and resources in isolating the target 26 
compounds. 27 
Within Seabiotech, metabolomics was used for quality control of the natural products 28 
and isolates to monitor the manifestation of a different metabolic profile between individuals, 29 
environmental alterations during growth and harvesting, post harvesting treatment, extraction 30 
and method of isolation, all of which can affect the efficacy of natural products. 31 
Through the metabolomics approach, the link between chemical profile and bioactivity 32 
pattern of the secondary metabolites is correlated. Metabolomics was widely applied in the 33 
bioactive screening of natural products although it has several advantages over the 34 
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reductionist approach. Metabolomic tools enhanced the identification and dereplication steps, 1 
as in bioassay-guided isolation work (Yuliana et al. 2011). Metabolomics was applied to 2 
dereplicate the biosynthesis of the natural product at different development stages of their 3 
biological source as well as simultaneously screen for the bioactivity. By using combinations 4 
of different analytical methods, the bioassay-guided isolation route was shortened and rapid 5 
dereplication of known activities was rapidly delivered (Ebada, et al; 2008). The SeaBioTech 6 
consortium encompasses the expertise in metabolomics.  VTT (Technical Research Centre of 7 
Finland) together with SIPBS developed MACROS and modified the algorithms of MzMine 8 
(version 2.10), a web-based differential expression analysis software (Pluskal et al. 2011) to 9 
efficiently detect the production of interesting secondary metabolites during the cultivation 10 
and production processes that would assist in maintaining or enhancing biosynthesis of the 11 
desired compounds (MacIntyre et al, 2015). An example is shown in Fig. 4. The results were 12 
integrated and coupled to an in-house database that includes DNP (Dictionary of Natural 13 
Products) and Antibase, a database of microbial secondary metabolites to further identify 14 
microbial secondary metabolites. Figure 4 presents the HRMS heatmap data as processed by 15 
Mzmine. The experiment analysed the production of anti-mycobacterial metabolites from a 16 
Vibrio sp. collected from the Atlantic coastline of the Northern Scottish Isles. 17 
Within the SeaBioTech project, metabolomics was applied at two levels: first, to 18 
identify and track active compounds highlighted by screening assays and second, to optimise 19 
the biotechnological production of active compounds in the later stages of the pipeline.  20 
Dereplication of secondary metabolites from promising isolates was achieved by HRFTMS 21 
(high resolution Fourier transform mass spectrometry) using the LTQ-Orbitrap and high 22 
resolution NMR. Through multivariate analysis, this enabled Fourier transformation of FID 23 
(free induction decay) data of multiple samples to statistically validate the parameters in the 24 
production of pharmacologically interesting secondary metabolites. Metabolomes were 25 
identified with the aid of existing high resolution MS and NMR records from in-house 26 
databases like DNP and AntiBase. MZmine is a software that was utilized to perform 27 
differential analysis on the mass spectral data from a vast number of sample populations to 28 
find significant expressed features of complex biomarkers between parameter variables. This 29 
would be further validated through available reference standards and two-dimensional 30 
homonuclear NMR e.g., TOCSY (total spectroscopy) and J-resolved NMR experiments to 31 
classify unknown by-products or degradants which may affect the quality of the desired 32 
product. The NMR metabolomic software from MNova was employed for metabolome 33 
recognition as well as to statistically validate the occurrence of metabolic by-products at the 34 
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different physiological states. VTT optimised the much-needed algorithms to analyse the 1 
huge dataset generated by the dereplication study as well as metabolomics profiling in 2 
monitoring and exploring the relationship between culture methods, diversity, bioactivity, 3 
and metabolome evolution in selected marine isolates. Efficient cultivation and production 4 
processes at a small volume scale fermenter are developed through real time metabolomic-5 
assisted optimization. Samplings were done inreal time for detailed metabolome analysis to 6 
fully characterize intermediates, by-products and degradants. Applying metabolomics for real 7 
time analysis will in parallel check the stability of the production of the desired components 8 
when changing certain fermentation parameters prior to scale up. In addition, a chemometric 9 
study was accomplished to support and develop algorithms that was adapted and optimised to 10 
target the bioactive secondary metabolites. Metabolomics has become a powerful tool in 11 
systems biology and it allowed SeaBioTech to gain insights into the potential of natural 12 
marine isolates for synthesis of significant quantities of promising new agents, and guide the 13 
manipulation of the environment within fermentation systems in a rational manner to select 14 
the desired metabolome.  Dereplication work was finalized for samples originating from 15 
Milos, Crete, and the geothermal vents of Iceland as well as those covering Scottish coastline 16 
and additional sample strains from the Antarctica region. Seventy-seven (77) bacterial 17 
samples were dereplicated from the NPMG-Orkney archive.  A total of 34 bacterial extracts 18 
from Milos and Crete were analysed, yielding SBT348 and SBT687 as the candidate strains 19 
for further compounds isolation and purification. While based on mass spectrometry profiles 20 
of strains from the Scottish coastline and the Antarctica region, three isolates revealed distinct 21 
patterns, KP130 (an unidentified bacteria isolated from Maud Rise, Antarctica), KP044 (a 22 
Streptomyces strain isolated from St. Andrews sediment) and KP121 (a Bacillus strain from 23 
Bransfield Strait, Antarctica). The metabolites responsible for these unique profiles were 24 
identified using principle component analysis (PCA) and found to be a series of polymers m/z 25 
363-1911 with spacing of 86 Da (KP130), a series of piscicides and antimycins known to be 26 
produced by Streptomyces spp. (KP044). These PCA outliers were also identified in the 27 
molecular network, demonstrating their complementary nature of metabolomic tools for 28 
secondary metabolite discovery. Metabolomic profiles have been documented into the 29 
SeaBioTech database. Metabolomes were dereplicated for priority strains while biosynthetic 30 
gene-based screening explored the presence of the genes for the respective secondary 31 
metabolite (WP4). However, bioactivity was used to prioritise strains for the WP7 pipeline 32 
(WP3). Extracts of priority strains were prepared from scale-up for further fractionation and 33 
isolation of bioactive secondary metabolites. Metabolomic-guided targeted isolation work 34 
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was done in parallel to and in support of the bioassay resulting to a quick identification of the 1 
active metabolites. A total of 65 natural products have been elucidated and have been 2 
documented in the SeaBioTech database which has been linked to Chemspider and PubChem 3 
databases (http://spider.science.strath.ac.uk/seabiotech/pure_compounds_show.php).  4 
 5 
 6 
Figure 3 – A) PCA scoring plot based on mass spectrometry data from all extracts. 7 
(Taxonomic identification data and bioactivities of the outliers (red dots) are shown in the 8 
plot.). B) Heat map based on mass spectrometry data. Outliers in PCA analysis plot are 9 
annotated *. 10 
  11 
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Figure 4 - Significant increase in bioactive metabolite production in Vibrio splendidus starts 1 
in Day 5 which steadily increases to Day10. However, only Day7 was found active against 2 
Mycobacterium marinum. 3 
 4 
 At VTT, an axenic Euglena gracilis microalga was introduced as a model organism 5 
for metabolic profiling. It was cultivated in 2 L stirred glass tank bioreactors in the presence 6 
of glucose under constant light or in the dark. The analyses showed that in light the glucose 7 
intake was delayed while the culture generated more biomass suggesting the contribution of 8 
photosynthesis. Lipidomic profiling by UPLC-QTof-MS in ESI+ mode (VTT) indicated that 9 
phosphatidylcholines were the prior lipid species, but in light cells accumulated large 10 
amounts of galactosyldiacylglycerols and ether-bonded lipids, while in dark medium-chain 11 
wax-esters were typically formed. LTQ-Orbitrap based metabolomic profiling (SIPBS), on 12 
the other hand, showed the richness of metabolites formed in dark especially, and numerous 13 
spectral library suggestions for terpenoids of marine origin were obtained. Bioactivity testing 14 
(AXXAM) was also indicating some HDAC6 and PPARα activities for the ethyl acetate 15 
extract of cells cultivated in the dark. 16 
3.34.3 Challenge 3: Sustainable modes of supply of raw materials 17 
Marine organisms have provided many promising bioactive compounds with exciting 18 
therapeutic potential. However, their development has been severely curtailed because of the 19 
difficulties in obtaining adequate amounts. Examples include anticancer agents, 20 
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ecteinascidin-743 and bryostatin. Ecteinascidin 743 (trabectedin, marketed as Yondelis®), 1 
was first isolated from the sea squirt Ecteinascidia turbinata in 1984. However, yields from 2 
the sea squirt were extremely low and for further drug development, 1 tonne of animals was 3 
needed to isolate 1 gram of trabectedin. It was only after 15 years that the supply problem 4 
was resolved by a semisynthetic process of starting with safracin B, which was obtained by 5 
fermentation of the bacterium Pseudomonas fluorescens. In the case of bryostatin, laboratory 6 
colonies of the bryozoan Bugula neritina exhibited a reduced number of symbionts and a 7 
reduction of byrostatin content thus implicating those bacterial symbionts as the true sources 8 
of the byrostatins. When some macro-organisms were placed in aquaculture in attempts to 9 
scale up production of a bioactive compound, the active material was lost, almost certainly 10 
because of loss of associated microbial species in the transfer from the wild to the cultured 11 
environment. 12 
SeaBioTech’s goal is to avoid such problems by basing much of its scale-up on the 13 
knowledge gained through its genomic and metagenomic studies of the gene clusters 14 
involved in synthesis of bioactive small molecules. There is extensive information on 15 
manipulating genes for non-ribosomal peptides and for polyketides. In addition, SeaBioTech 16 
explored the biosynthesis of marine polysaccharides, for which much less is known. This 17 
aspect of the project, its background and the advances made by SeaBioTech, will be 18 
explained in detail in the following section. 19 
3.3.14.3.1 Sustainable production of macromolecules at the lab scale by metabolic 20 
engineering 21 
Microbes in extreme environments often adapt through production of extracellular 22 
polysaccharides (EPS). They are highly hydrated, which helps to deter desiccation, and they 23 
mediate adhesion to inert surfaces or living tissues, which is important for colonization of 24 
host organisms and the formation of biofilms. Often these polysaccharides have novel and 25 
unusual characteristics and (Jia et al. 2007; Nicolaus et al. 2010) that can be exploited in 26 
various fields - in the food, pharmaceutical and cosmetics industries as emulsifiers, 27 
stabilizers, gel agents, coagulants, thickeners and suspending agents and in high value 28 
medical applications such as in tissue engineering and drug delivery (Wingender et al. 1999). 29 
Due to low production levels, few of these organisms have been exploited commercially. It 30 
follows that they are therefore basically untapped as a genetic resource for these activities. 31 
SeaBioTech explored the possibility of accessing these sources by developing a platform for 32 
production of tailor-made polysaccharides and oligosaccharides. While bioprospecting 33 
platforms have proven their value in mining natural genetic resources, the exploitation of 34 
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promising leads is often hampered by low production yields. This is especially true as regards 1 
complex carbohydrate molecules - oligosaccharides, polysaccharides and glycosides. These 2 
limitations can in theory be overcome by pathway engineering of the source organism. 3 
Biosynthetic pathways can be influenced at three different levels: synthesis of sugar 4 
nucleotide precursors; assembly of the repeating unit; and polymerization with concomitant 5 
export. By modifying the expression of single genes or groups of genes the conversion 6 
efficiency of the chemical entities involved can be increased, and therefore, enhance EPS 7 
yield (Ruffing & Chen 2006). While highly justifiable in many cases, such an approach 8 
necessitates the time-consuming work of developing genetic tools, selectable markers, 9 
transformation methods and ideally species-specific expression vectors for each organism. 10 
An alternative approach to make use of these genetic resources is to develop a versatile 11 
polysaccharide production microbe with suitable genetic tools for hosting genes from other 12 
organisms. Such genes could exert their effects in the biosynthetic pathway in variety of ways 13 
depending on the gene, by introducing novel mono-saccharide components and/or other 14 
substituents and by forming new linkages. Metabolic engineering of platform organisms for 15 
producing novel oligosaccharides and polysaccharides derivatives presents substantial 16 
challenges. Microbial polysaccharides are species-specific, highly heterogeneous polymers. 17 
These glycans include many unusual sugars not found in vertebrates, such as variously 18 
modified hexoses, non-carbohydrate substituents and an oligosaccharide sequence-repeating 19 
unit that can vary in size depending on the degree of polymerization. Besides requiring very 20 
complex synthetic machinery, the cellular context also matters, e.g. interference with energy 21 
metabolism, for synchronization/co-regulation of synthesis pathways, post-synthesis 22 
modifications and secretion mechanisms. Successful metabolic engineering of EPS-23 
producing strains has been reported. In Acetobacter xylinum, the disruption of the diguanylate 24 
cyclase gene led to enhanced production of bacterial cellulose with altered structural 25 
properties (Bae et al. 2004) and it has been shown that inactivation of the C5 epimerase in P. 26 
fluorescens led to the production of the homopolymer polymannuronate. It is expected that 27 
continued effort in this field will open up an enormous potential for the biotechnological 28 
production of biopolymers with tailored properties suitable for various high value 29 
applications (Morea et al. 2001). The assembly of extracellular polysaccharide involves a set 30 
of genes that are often clustered in the bacterial chromosome in separate regions. This 31 
arrangement allows a simple mechanism for changing capsule types by merely swapping 32 
different gene cassettes. Genes in one particular region can encode enzymes involved in 33 
nucleotide sugar formation and capsule-specific transferases whereas genes in other regions 34 
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encode type independent transport activities required for movement of the polysaccharides 1 
across the inner membrane and periplasm. In other instances, synthases have formed 2 
membrane pores through which the polysaccharide is transported concomitantly with 3 
synthesis. This has been shown, for example, in hyaluronate synthetase in Streptococcus 4 
(Tlapak-Simmons et al. 2004) and suggested by MATIS as the most plausible model on 5 
synthesis/transport mechanism of periplasmic beta glucan oligosaccharides involving a 6 
multidomain glucosyltransferases in Proteobacteria (Hreggvidsson et al. 2011). Besides a 7 
region coding for a Leloir glucosyltransferase of family GT2, another region codes for a 8 
domain belonging to a Non-Leloir glucosyltransferase of family GH17, a trans-membrane 9 
domain is predicted to form a membrane pore through which the newly synthesized glucan 10 
chain, product of GT2, is transported. The periplasmic GH17 enzyme domain then further 11 
modifies the nascent β-glucan leading to the formation of branched and cyclic OPGs. The 12 
specific features of polysaccharide synthesis suggest that alteration of polysaccharide 13 
structure can be achieved by region, gene, and even domain swapping in their synthetic 14 
pathways and individual glucosyl transferases.  15 
Glucosyltransferases are key enzymes in the anabolic polysaccharide biosynthesis, 16 
and microbial genome sequencing gives unprecedented access to this type of enzymes. They 17 
can now be systematically identified and compared with various bioinformatic tools. 18 
Valuable targets can be rationally selected and by appropriate molecular techniques they can 19 
be inserted into target production organisms and their effect on the biosynthesis pathway 20 
analysed by various methods. Glucosyltransferases catalyse the transfer of a glycosyl group 21 
from a high-energy donor or oligosaccharide to an acceptor. The Leloir type of enzymes 22 
utilize nucleotide phosphosugars (NP-sugar-dependent) as donors producing a nucleotide and 23 
saccharide as reaction products and it has been shown that microbial  lucosyltransferases are 24 
more versatile than their eukaryotic counterparts. 25 
A number of Leloir multigene families have been identified and an important focus of 26 
the bioprospecting effort was analysing and selecting an array of glucosyltransferase genes 27 
for cloning into a platform polysaccharide producing thermophile for expression, and 28 
structural and functional studies of the resultant effects on source oligosaccharide. The source 29 
polysaccharide was analysed for structural alteration including changes in monosaccharide 30 
composition linkage types, repeat structure and the degree of branching. Relevant accessory 31 
enzymes was also defined and co-expressed with selected transferases if needed. Of these, 32 
enzymes for generation of activated sugars are most critical. Their requirement is dependent 33 
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on which glucosyl transferase will be selected for expression in the hosting system and the 1 
inherent capabilities of the host.  2 
The platform species envisaged for polysaccharide production needed to fulfil certain 3 
criteria. It should (a) produce polysaccharides in high quantities, (b) be able to import a 4 
variety of sugar to be used as acceptors, (c) produce a great variety of activated sugars, at 5 
least many important ones, and (d) produce few and low amounts of side products. The ideal 6 
strain chosen for such polysaccharide production is the thermophilic marine bacterium 7 
Rhodothermus marinus, which served as the “model organism” in this project. Under certain 8 
conditions, it produces large quantities of EPS. The organism has a broad substrate range, 9 
degrading a large variety of polysaccharides and growing on their constituent uronic acids, 10 
hexoses and pentoses. R. marinus showed diverse metabolic activity and is easily cultivated. 11 
The genome has been fully sequenced and various genetic tools and selectable markers have 12 
been developed in previous projects of the Matís group. 13 
R. marinus belongs to the phylum Bacteroidetes and it was first isolated from the 14 
coastal geothermal area in Iceland. It is an aerobic heterotroph that grows at temperatures of 15 
up to 77°C (Bjornsdottir et al. 2006). It has been subject of considerable research much of 16 
which has been devoted to its thermostable enzymes on account of their biotechnological 17 
potential, particularly polysaccharide degrading enzymes. Interestingly, several of these 18 
enzymes are secreted and exhibit optimum activities at 80-100°C, which far exceeds the 19 
optimum for growth. Examples are cellulose, xylan and mannan degrading enzymes, some of 20 
which have been studied in great detail (Dahlberg et al. 1993; Hreggvidsson et al. 1996; 21 
Nordberg et al. 1997; Gomes & Steiner 1998; Abou Hachem et al. 2000; Politz et al. 2000; 22 
Wicher et al. 2001; Crennell et al. 2002; Abou Hachem et al. 2003). The work by MATIS 23 
has focused on developing gene transfer and genetic selection for the genetic engineering of 24 
R. marinus (Ernstsson et al. 2003; Bjornsdottir et al. 2005; Bjornsdottir et al. 2007; 25 
Bjornsdottir et al. 2011). R.marinus was considered suitable for genetic studies because of its 26 
aerobic nature, competence growth in the defined media. Importantly, it exhibited 27 
reproducible growth on solid media, and clonal populations were easily obtained. Restriction 28 
negative host strain has been established and expression vectors and selectable markers have 29 
been developed. Selectable markers, initially, biochemical and genetic properties of the 30 
species were poorly known and mainly restricted to single characterized proteins and genes, 31 
none of which could serve as a selective marker. The preferred antibiotic selection for 32 
thermophiles was based on the thermos-adapted kanR determinant, which was unsuitable for 33 
R. marinus because of its natural resistance to aminoglycosides. In continuing work, two 34 
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selective markers were identified, trpB and purA, which encode proteins of the tryptophan 1 
and adenine biosynthetic pathways, respectively. A restriction deficient R. marinus isolate 2 
was chosen as a recipient for gene transfer experiments (Bjornsdottir, et al. 2011). The 3 
endogenous trpB and purA were deleted from the chromosome of the recipient, making it 4 
compatible with both Trp+ and Ade+ selection. Moreover, the deletions prevented both the 5 
development of spontaneous revertants and unintended marker integration. Expression 6 
vectors, a small, cryptic R. marinus plasmid, pRM21, of 2935 bps (Ernstsson et al. 2003) 7 
served as the starting point for constructing R. marinus–Escherichia coli shuttle vectors 8 
(Bjornsdottir et al. 2005). They contained the R. marinus trpB gene expressed from the 9 
promoter of the R. marinus groESL operon. These vectors served as basis for the construction 10 
of cloning vectors and allowed for the cloning and expression of foreign genes as well as 11 
induced expression in R. marinus following temperature shifts. Two reporter genes were also 12 
identified, allowing for the investigation of R. marinus promoter activities in vivo 13 
(Bjornsdottir, et al. 2007). Both random and site-directed inactivation of R. marinus genes 14 
has been implemented. Unmarked deletions were generated resulting in a double mutant with 15 
the genotype ΔtrpBΔpyrA. Here, the marker carried by the vector, outside homologous 16 
sequences, is lost through resolution of co-integrate. Subsequently, in-frame deletions using 17 
the trpB and the purA marker genes have been introduced. The selection efficiency of the 18 
strain was e.g. demonstrated by insertional mutagenesis of the carotenoid biosynthesis genes 19 
crtBI. The resulting Trp+, CrtBI- mutants were colourless rather than orange-red 20 
(Bjornsdottir, et al. 2011). Also, marked deletions were obtained by performing gene 21 
replacements with linear molecules, which yielded double-crossover recombinants in a single 22 
step (Bjornsdottir, et al. 2011). The existence of selective markers and expression vectors 23 
enable rational genetic manipulation of Rhodothermus, which can result in altered metabolic 24 
pathways and novel products. 25 
The extensive recombinant techniques available for R. marinus, existing genome 26 
sequence data, as well as broad substrate range and saccharide conversion features makes R. 27 
marinus feasible for metabolic engineering and eventually a versatile platform organism for 28 
production of structurally modified polysaccharide derivatives. By using metabolic 29 
engineering approaches, R.marinus was streamlined for production of complex molecules by 30 
eliminating the formation of side products by increasing gene dosages of critical genes, 31 
eliminating and/or modifying regulation mechanisms. By hosting appropriate genes from 32 
other organisms synthetic pathways can modified and consequently structure and properties 33 
of a target molecule can be altered. 34 
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3.3.24.3.2 Sustainable production of secondary metabolites at the industrial scale 1 
In traditional biotechnology, all industrial manufacturing processes began (and begin) with 2 
plate cultivation, followed by scale transfer to liquid culture and further scale-up. (Chen et al. 3 
2011; Voulgaris et al. 2011; Finn et al. 2010; Fazenda et al. 2010; El-Sabbagh et al. 2008; Li 4 
et al. 2008). These steps, for some marine isolates, can be problematic and can be associated 5 
with a loss or reduction in the synthesis of desired metabolites or formation of unwanted by-6 
products (Pettit 2011). The immense biodiversity apparent in the marine environment is a 7 
potentially rich source of novel antibiotics, other secondary metabolites, and metabolic 8 
potential (Pettit 2011), but in order to fully exploit this potential we must take interesting 9 
activities often noted under lab conditions and transfer them to industrial scale production. 10 
However, biomanufacturing using marine microorganisms presents several unusual 11 
challenges distinct from those encountered when manufacturing bioproducts from 12 
conventional terrestrial microorganisms. In part, these reflect the origins of the isolates 13 
themselves (source microbes). They include the use of media containing salt at moderate to 14 
high levels (0.43M to 2.5%) (Durand et al. 1993; Nakagawa et al. 2005; Slobodkina et al. 15 
2008), which can present corrosion and wear issues on seals and bearings of fermenters. The 16 
range of temperature optima for cultivation of marine microbes also presents challenges to 17 
the biotechnology industry, with interesting bioactivities noted in marine microbes with 18 
psychrophilic (4o C) (Burgaud et al. 2009) to thermophilic optimal temperatures (85o C) 19 
(Andrianasolo et al. 2009). Since the biotechnology industry basically uses processes and 20 
fermenters designed for organisms with temperature optima from around 25 to 40 oC 21 
(Matthews 2008), these unusual temperature requirements required significant re-design of 22 
plant in terms of heat removal and mass transfer (low O2 solubility as temperature rises). 23 
Even when isolation of interesting fungal microbes from marine sources using agar brine 24 
plate cultures rather similar to the industrial workhorse Aspergillus is successful, this does not 25 
easily lead to new industrial products due to some of the barriers discussed above 26 
(Raghukumar et al. 2008). Other hurdles to rapid industrial exploitation include the use of 27 
unusual energy sources (H2) (Nakagawa et al. 2005) which are unfamiliar to the mainstream 28 
fermentation industry, and dangerous, or unusual substrates or toxic by-products (e.g.H2S 29 
(Slobodkina et al. 2008)) also unfamiliar to the bioprocess industries and with significant 30 
safety implications. Such isolates usually are exposed to low levels of dissolved oxygen due 31 
to the sparing solubility of oxygen in seawaters, whereas the modern fermentation industry is 32 
geared up to deliver products largely from mesophilic cultures in highly aerated and agitated 33 
fermenters (Matthews 2008). On occasions, the early treatment or storage of natural isolates 34 
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leads to loss or reduction in metabolite synthesis on scale up. The perception of strain 1 
instability is a critical barrier.  Despite the above, there is no fundamental reason why marine 2 
isolates should be inherently less stable than terrestrial, and even those from extreme 3 
environments have been shown to be amenable in some cases to cultivation under non-4 
extreme conditions (Pettit 2011). Overall, though these hurdles and bottlenecks contribute to 5 
a less than certain and lengthier path to market for marine products when compared to 6 
terrestrial derived products arising from a narrower ecological range, and may well inhibit 7 
any further exploitation of an activity. The challenge is to match huge biodiversity in growth 8 
characteristics with a bioprocessing industry, which is largely based upon a very limited 9 
range of optimised process to effectively and efficiently scale up interesting activities from 10 
bench scale to industry volumes. One approach to this is simply to move novel activities from 11 
less tractable marine isolates to industrial workhorse organisms, which the bioprocessing 12 
industry is familiar with and accustomed to scaling up. Pathway and metabolic engineering is 13 
widely used in the biotechnology industry (Andersen & Nielsen 2009), and this may well 14 
overcome some of the challenges noted. Further, the path to industrial production for both 15 
source microbe-derived and novel construct-derived products can be made more certain and 16 
faster, by applying a combination of best industrial manufacturing practice for new 17 
fermentation products, together with novel in process real-time monitoring and multivariate 18 
analysis techniques (Chen et al. 2011, Roychoudury et al. 2007). These techniques would 19 
enhance the flow of process data in early development phase and put the physiology of these 20 
marine microbes and constructs on a sounder basis, hence ensuring the acceleration of 21 
industry exploitation (Chen et al. 2011, Roychoudury et al. 2007), faster delivery of marine 22 
products to markets, and safer and more predictable scale up.  23 
3.44.4 Challenge 4: Legal aspects relating to access to marine 24 
bioresources 25 
Bioprospecting can be defined as commercially focused research and development that uses 26 
naturally occurring compounds. It includes steps from first discovery, through patenting, 27 
improvement, development and commercialisation. A simple breakdown of bioprospecting 28 
is: Phase 1: on-site collection of samples; Phase 2: isolation, characterization and culture of 29 
specific compounds; Phase 3: screening for potential uses, such as pharmaceutical or other 30 
uses; and Phase 4: product development and commercialization, including patenting, trials, 31 
sales and marketing (Leary, 2004). Bioprospecting using a country’s genetic resources is 32 
covered by the United Nations Convention on Biodiversity (the CBD) (Harvey and Gericke 33 
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2011). This will extend to a coastal country’s Exclusive Economic Zone (EEZ) and its 1 
Continental Shelf, as defined by the United Nations Convention on the Law of the Sea 2 
(UNCLOS – article 56(1) and article 77(1)). However, there is no international treaty that 3 
regulates bioprospecting in the water column above the continental shelf or in areas beyond 4 
national jurisdiction (‘the deep sea’, UNCLOS article 87(1)). Instead, each state is required to 5 
regulate the activities of its nationals in those areas, particularly with concern to avoid 6 
environmental damage. Aspects of the regulatory framework may distinguish between 7 
bioprospecting (as defined above) and the undertaking of scientific research without 8 
commercial motive (Leary, 2004). To summarise the present legal position in relation to 9 
marine bioprospecting: · Coastal States have the sovereign right to allow, prohibit, and 10 
regulate marine bioprospecting and/or scientific research in the water column of their EEZ, 11 
and on the seabed (including the subsoil) until the farther of either the limits of their EEZ or 12 
the outer edge of their continental shelf. · State regulation is subject to a number of 13 
international obligations incumbent upon coastal States, including in relation to the protection 14 
and preservation of the environment and to the conservation and sustainable use of marine 15 
genetic resources. Significantly, such regulation may also be impacted by access and benefit-16 
sharing mechanisms established pursuant to the CBD; 17 
· All States enjoy free access to marine genetic resources located seaward of other States’ 18 
EEZs and continental shelf. They have jurisdiction to allow, prohibit, and regulate marine 19 
research and bioprospecting activities conducted by their nationals and/or vessels flying their 20 
flags; free access is subject to a number of international obligations incumbent upon coastal 21 
States, including in relation to the protection and preservation of the environment and to the 22 
conservation and sustainable use of marine genetic resources. Significantly, such free access 23 
is also subject to the duty of States to cooperate for the conservation of marine genetic 24 
resources. The mechanisms of benefit sharing and the related legal aspects of research on 25 
marine bioresources is a very important aspect of this project in collaboration with other 26 
marine biotechnology programmes that includes PharmaSea and MicroB3. Many marine 27 
ecosytems are still little studied, but their vast and novel biodiversity offers many possibilities 28 
for the discovery and development of novel industrial products. In spite of considerable 29 
previous work, particularly the CBD, many aspects remain unresolved. The discussion of 30 
equitable benefit sharing among interested parties often gets stuck because it tends to focus 31 
on percentages of a future income from possible blockbuster products. Another equally 32 
important aspect is to evaluate and discuss the mechanisms that can be used for more short 33 
term, more secure, and non-monetary ways of benefit sharing from bioprospecting activities, 34 
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as is highlighted in the Nagoya Protocol to the CBD. These are particularly important and 1 
relevant when it comes to sampling and research on novel ecosystems and unusual natural 2 
phenomena, particularly in the world oceans since they are still more underexplored than on 3 
land. SeaBioTech addressed the legal aspects in a concise way doing a direct evaluation of 4 
the legal and access issues connected to sampling in the project itself. Another task was to 5 
find and study some key cases of this sort that have come up recently, in particular in relation 6 
to novel marine ecosytems. Two such examples are the smectite geothermal cones north of 7 
Iceland and the Tufa columns in Greenland. SeaBioTech worked with other marine 8 
biotechnologically oriented projects to assist in the interpretation and application of best 9 
practice and conforming to current national, European and international legislations as well 10 
as the most recent Nagoya Protocol.  11 
 In addition to the close liaison maintained with the other KBBE Bioprospecting 12 
projects, SAMS, acted as a link between SeaBioTech and the ESFRI road map Research 13 
Infrastructures (RIs): EMBRC  and MIRRI (MIcrobial Resource Research 14 
Infrastructure).This has involved relevant CBD related input to the development of the 15 
H2020 EMBRIC project. SAMS has also been responsible for providing advice to the 16 
government of the Republic of the Seychelles on building a Blue economy, including the 17 
need for managing access to MGR. 18 
3.54.5 Challenge 5: Improving access to marine biotechnology data 19 
through an EU platform 20 
As highlighted in the recent position paper ‘Marine Biotechnology: a New Vision and 21 
Strategy for Europe’ (European Science Foundation, September 2010), there is a need for a 22 
“central European information portal, which provides a one-stop-shop for state-of-the-art 23 
reports on novel discoveries and success stories, challenges and applications”. Currently, 24 
there are few sources of comprehensive information relevant to marine biotechnology. The 25 
Coordination and Support Action project under FP7, Marine 4Genomics Users created a 26 
“single entry-point to marine genomics knowledge”. However, this did not encompass 27 
information relating marine samples to bioactivity test results, comparable to the US’s NIH 28 
Roadmap initiative with results being openly available in the PubChem BioAssay database. 29 
For general information on marine biodiversity, there is the National Ocean Service, which is 30 
run by the US government agency, the National Oceanic and Atmospheric Administration, 31 
and there is MarineBio in the USA, which is a non-profit organisation that tries to provide a 32 
broad range of information relating to marine conservation and science. However, neither 33 
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covers details of species in particular environments or bioprospecting information. For 1 
extremophiles, there is a developing resource hosted by the Indian organisation, the Institute 2 
of Genomics and Integrative Biology, although this is not focused on marine species and does 3 
not cover bioprospecting. As described earlier, under challenge 1 (quality of marine 4 
resources), there is also very limited access to physical samples from marine environments. 5 
Hence, SeaBioTech developed and established both an information portal and a physical 6 
repository of samples for further genetic analysis and for use in additional bioactivity testing.  7 
SeaBioTech activity complemented other EU-funded projects such as FP5 MarGenes, FP6 8 
Diatomics, FP6 Marine Genomics Network of Excellence, FP7 Micro B3 (Biodiversity, 9 
Bioinformatics, Biotechnology), and FP7 MAREX. It also linked to other projects funded 10 
under the present call. In that way, SeaBioTech provides a major contribution in achieving 11 
another recommendation of the ESF’s position paper on marine biotechnology towards the 12 
creation of a virtual European Marine Biotechnology Institute. 13 
 SeaBioTech has provided input to the PharmaSea case studies: Role of biorepositories 14 
and impact of proposed EU regulation on ABS; the European blue biotech community’s 15 
preparedness and response to the implementation of the Nagoya Protocol.   16 
5 Conclusion: Impacts and Future Insights  17 
In this section, we summarise the project’s achievements to answer the challenges set by the 18 
consortium. The achieved milestones along with the encountered confrontations and some 19 
strategies used to yield to the challenges set by the SeaBioTech consortium are presented on 20 
Table 1.   21 
3.65.1 A reproducible quality of marine resources 22 
Addressing the first challenge on quality of marine resources collected during the project’s 23 
lifetime, the consortium was given the opportunity to investigate some of the unique 24 
environments/habitats on earth, isolate/characterize microbial species living there and create 25 
large strain collections for biotechnological exploitation. Some of the isolated strains were 26 
characterized by high novelty and biotechnological potential as they showed very low 27 
similarity with any other previously characterized bacteria. New knowledge was gained about 28 
gene diversity in extreme environments, as well as valuable information about environmental 29 
microbial functioning through the application of modern metagenomic deep-sequencing 30 
techniques. Genomic sequence data by UWUERZ has revealed the presence of a large 31 
fraction of putatively silent biosynthetic gene clusters in the genomes of actinomycetes that 32 
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encode for secondary metabolites that remain silent under standard fermentation conditions. 1 
Our work has provided here novel insights into actinomycete biodiversity as well as into the 2 
effects and consequences of elicitation of secondary metabolism in actinomycetes.  Huge 3 
metagenomics datasets were created and used as a source for bioprospecting. WP2 served as 4 
the foundation of SeaBioTech discovery pipeline. By focusing on previously unexplored 5 
environments, WP2 attempted to increase the odds of discovering novel bacterial species that 6 
would contain novel bioactive compounds of potential economic interest. Indeed, WP2 7 
supplied the other work packages with novel cultivable strains holding a great potential for 8 
the discovery of novel natural products of high-added value. In addition, through Seabiotech 9 
sampling campaigns knowledge on the activity of the extreme environments of the Hellenic 10 
Volcanic Arc was exploited demonstrating the need of a monitoring program for this 11 
dangerous environment (Rizzo et al., 2016).  12 
3.75.2 An improved and integrated technology for drug discovery 13 
For the improvement in technical aspects, SeaBioTech integrated metabolomics-assisted 14 
methodology with systems biology and functional bioassays increasing the ability to divulge 15 
positive hits that proved to be affordable, innovative and efficient method (MacIntyre et al 16 
2014) to separate, elucidate the structure, and identify the bioactive metabolites. Novel and 17 
underexplored species of marine microorganisms were investigated for the first time as 18 
potential sources of novel therapeutics and they provide positive indications that lead 19 
compounds can be isolated and progressed to address significant unmet medical needs (e.g., 20 
cancer, infections against, metabolic syndrome and inflammation) and threatening parasitic 21 
infections for aquaculture. WP3 partners in charge of the screening activities improved the 22 
performance and throughput of the assays, to comply with the requirement to process a 23 
remarkably high number of extracts, fractions and compounds of marine origin. Major 24 
improvements were obtained for the development of automated, high-throughput screening 25 
platform to provide cell-based assays for the detection of hits with anti-cancer activities, in 26 
particular for cell proliferation (HDL). Moreover, assay systems were modified to achieve a 27 
suitable robustness to screen complex marine extracts and subsequently to produce more 28 
accurate and reliable results (SIPBS, AXXAM).  29 
The personalised medicine market worldwide is estimated to be over €400 billion and 30 
the core diagnostic and therapeutic segment of the market is estimated at over €40 billion. 31 
The need to address this market and the benefit of doing so is supported by many facts, 32 
including a 75% increase in personalised medicine investment over the last 5 years and 30% 33 
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of all pharma companies now require compounds in R&D to have patient-relevant treatments. 1 
The potential novel marine products identified through the SeaBioTech consortium may 2 
enable such therapeutics to progress through the R&D process. In particular, prospective lead 3 
compounds have been isolated with a potential to address therapeutic indications for human 4 
health such as cancer, bacterial infections and metabolic syndrome, and to develop an 5 
effective treatment against the fish parasite L. salmonis, which represent a major threat for 6 
aquaculture. In addition, the knowledge gained through SeaBioTech concerning assay 7 
development and screening of complex marine extracts may directly or indirectly translate 8 
into new opportunities for the CROs to expand their potential market and for pharmaceutical 9 
and life science companies to undertake novel R&D projects. In addition, the phenotypic 10 
assay performed on the fish parasite of aquaculture plants Lepeophtheirus salmonis was also 11 
optimized to increase its capacity and processivity, thereby expanding the possibility to 12 
screen extracts and fractions of marine source (PHARMAQ). The lead compounds isolated at 13 
the end of the SeaBioTech collaboration have the potential to be evolved into novel 14 
therapeutics. The availability of novel therapeutics for human health and aquaculture will 15 
directly contribute towards improving quality of life, health, employment and economic 16 
strength.  17 
Automated dereplication and chemical profiling aid screening for diversity and 18 
novelty were established in WP5. Marine invertebrate-associated symbiotic bacteria produce 19 
a plethora of novel secondary metabolites, which may be structurally unique with interesting 20 
pharmacological properties. Selection of strains usually relies on literature searching, genetic 21 
screening and bioactivity results, often without considering the chemical novelty and 22 
abundance of secondary metabolites being produced by the microorganism until the time-23 
consuming bioassay-guided isolation stages. The development of a comprehensive 24 
metabolomics workflow pathway including an in-house developed Excel macro embedded 25 
with a database made it possible to rapidly dereplicate higher number of strains, providing 26 
putative identities of known metabolites in each extract. It is also shown that the dereplication 27 
results can also be correlated with bioassay screening results to support drug discovery efforts 28 
with the objective of both finding a bacterial isolate that has a unique diverse chemistry and is 29 
biologically active. Overall, this shows that metabolomics approaches are worthwhile for the 30 
selection of strains for the isolation of novel natural products and that this methodology 31 
reduces redundancy in drug discovery programs.  Additionally, we have shown through PCA 32 
and heat map analysis that strains with nearly identical 16S rRNA sequences do not 33 
necessarily produce the same secondary metabolites. 34 
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Metabolomic-assisted isolation of target compounds efficiently improved the 1 
purification of the bioactive secondary metabolites. Multivariaye analysis that included 2 
Principal Component (PCA), hierarchical clustering (HCA), and orthogonal partial least 3 
square-discriminant analysis (OPLS-DA) were used to evaluate the HRFTMS and NMR data 4 
of crude extracts from different fermentation approaches. Statistical analysis identified the 5 
best culture one-strain-many-compounds (OSMAC) condition and extraction procedure, 6 
which was used for the isolation of novel bioactive metabolites. As a result, new natural 7 
products can be isolated from cultivated broth cultures (described under section 4.2.2). New 8 
natural products with novel mechanisms of actions were isolated. Biologically active 9 
compounds were isolated and purified from prioritized strains. SBT345 (Streptomyces sp.) 10 
showed anti-oxidant, anti-cancer cell lines (DLD-1, HCT116) activities, and some activities 11 
in the enzymatic reactions. Compounds SBT1620 (phencomycin), SBT1621 (tubermycin B), 12 
SBT1186 (benzethonium), and SBT1187 (ageloline A, new compound) were isolated from 13 
SBT345. SBT1877 showed anti-oxidant and anti-Chlamydia trachomatis activities. SBT017 14 
(Rhodococcus sp.) yielded 16 pure compounds after scale-up, one of which was elucidated as 15 
isohalobacillin B. SBT0027 (Vibrio splendidus) yielded 27 pure compounds, 7 of which are 16 
bis-indole analogues with strong to medium potency against Mycobacterium marinum. Three 17 
analogues are new. Other pure compounds from SBT0027 consisted of diketopiperazines, 18 
long chain amines, and hydroxylated fatty acids, the activities of which still need to be 19 
determined. SBT167 (Polysiphonia lanosa), an algal macro-epiphyte yielded the di-bromo-20 
dihydroxylated-benzaldehyde as its major component. SBT167 was found to be active against 21 
parasitic sea lice and in several enzymatic assays against metabolic diseases. From the 22 
Icelandic collection, new BHA congeners bioactive against metabolic diseases were isolated. 23 
3.85.3 A sustainable production of raw materials 24 
The last technical brick for the industry is the sustainability of the production of raw 25 
materials not only at lab scale but also at industrial scale. The program has developed 26 
standard operating protocols for the growth and exploitation of resources from both natural 27 
isolates and construct microorganisms, developed by identifying, isolating and genes of 28 
interest from marine species and inserting them into organisms which are regarded as 29 
industry work horses e.g. Escherichia coli.  Scale up predictions for processes developed in 30 
WP10 were formulated by the fermentation group in SIPBS.  Accelerated process 31 
development has been achieved either by utilizing powerful gene technologies to create 32 
construct organisms or by utilizing bioprocessing techniques with metabolomics with source 33 
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microorganisms to identify bottlenecks in the relevant catabolic pathways. Both of these 1 
techniques resulted in successful bioprocess intensification of the relevant target compounds 2 
or enzymes. Industrial partners identified appropriate target compounds, which allowed us to 3 
selectively mine the gene pool of the marine organisms for useful enzymes. Suitable 4 
protocols were then generated for the bioprocess and put together in a Process Manual. 5 
Combining the novel gene technologies, metabolomics and ability to rapidly scale 6 
processes, using clearly defined standard operating procedures, is the unique aspect of the 7 
programme. This is of particular interest to industrial partners and significantly benefits both 8 
the companies involved in SeaBiotech and the scientific community in general. Many of the 9 
techniques can now be regarded as generic and could be exploited elsewhere on other 10 
projects and processes. Genes from source organisms, which express novel enzymes, have 11 
been successfully inserted into industry workhorse organisms and have been successfully 12 
scaled up. Such enzymes have novel capabilities and are successfully utilised by some 13 
industry partners. In particular generating new construct microorganisms has allowed the 14 
exploitation of enzymes, e.g. alginate lyases and thioesterases  to name but two, capable of 15 
utilising different kinds of feedstocks and which allow processes which previously suffered 16 
from bottlenecks to work effectively and efficiently.  This is a significant scientifc 17 
breakthrough as the potential for industry is great. A novel polymer was isolated from 18 
Colwellia sp. The organism has been successfully grown at scale in WP7 and a spin off 19 
project has developed between SAMS and Unilever.  New bioactive compounds have been 20 
identified (WP3) and tested at scale in WP7. Initial trials have shown the organisms from 21 
which the bioactives are isolated can be grown at scale but research to improve the 22 
productivity of the bioactives continues.   23 
The generation of new enzymes and polysaccharides will have considerable influence 24 
on the economies of the consortium partner companies and on the economy of the EU and 25 
also on global markets.  The enzymes in particular have significant industrial capability and 26 
applications will be numerous. The ability to use new substrates , previously un-useable 27 
either because it was not scientifically possible or because process economics were not 28 
favourable,  will have significant impact on increased process efficiency, improved supply 29 
chains (substrate choice increases) and reduction in  upstream costs . As seen above impact 30 
will not just be industrial as IGZ see significant potential in the health care market where 31 
opportunities in drug discovery from marine derived biocatalysts are highly relevant to the 32 
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biosynthesis of compounds for the treatment of disease.  The market share for companies 1 
who use SeaBiotech derived enzymes and compounds could expand rapidly. 2 
3.95.4 A harmonized legal position on marine bioprospecting 3 
SeaBioTech liaised closely with, and contributed to, common areas of activity dealing with 4 
legal/ethical aspects being undertaken in the parallel EU funded projects: MICROB3, 5 
BlueGenics and PharmaSea. An overarching group of experts was formed, i.e. the Advisory 6 
panel of policy and legal experts (APPLE). APPLE, an advisory board brought together the 7 
breadth of experience, legal, scientific and commercial, necessary to address the critical 8 
policy and legal barriers which currently hinder progress in innovative marine biotechnology 9 
in Europe. The projects have worked together on these aspects to avoid duplication of effort 10 
and enable a wider-reaching and more global approach of benefit to these consortia and 11 
beyond.  During the lifetime of the project the legal implications to bioprospecting have 12 
changed status with the implementation of the Nagoya protocol, which became legally 13 
binding from the 12th of October 2014. An overarching, generic Material Transfer 14 
Agreement (MTA), conforming to the requirements of the Nagoya Protocol has been 15 
developed by Microbio3. This has, with minor adjustments, been applied across the projects. 16 
SeaBioTech contributed to the development, structure and content of the PharmaSea 17 
Deliverable on development of web-based, interactive, toolkit to assist Marine Genetic 18 
Resource (MGR) practitioners in navigating the different legal and policy regimes involved 19 
in access to MGR and associated benefit sharing. This area has rapidly developed and on-line 20 
resources associated with the CBD Clearing House are available to users/ potential users of 21 
biological resources. Work undertaken by APPLE, particularly the PharmaSea legal team, has 22 
resulted in considerable progress with respect to the developing of possible solutions to the 23 
implications of the collection of materials in areas beyond the Economic Exclusive Zone 24 
(EEZ) i.e. in Areas Beyond National Jurisdiction (ABNJ). These were presented at the UN 25 
HQ, New York on16-20th June 2014 for consideration for possible future proposed changes 26 
to the UN Common Law of the Sea (UNCLOS). 27 
3.105.5 A cCentralised biobank repository and database of information 28 
SeaBiotech created a centralized tool to organise the marine biodiscovery pipeline through a 29 
biobank repository and database of information for marine strains which included names of 30 
the identified marine organisms, compounds and extracts, their bioactivities, the cutting-edge 31 
methods in identification, elucidation, metabolic engineering to be further used for industrial 32 
purposes with all related procedures on legal process for companies, academia, and legal 33 
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authorities. The assembly of a centralized repository of marine extract and compounds of 1 
marine origin was amongst the major legacy of Seabiotech. The centralized repository 2 
contains at the end of the project 3209 samples of marine origin, including 1140 crude 3 
samples and 606 fractions plated in ready-to-screen format and 63 pure compounds. In 4 
addition, the repository contains samples which were received in a too small amount for 5 
general screening. Thus, they were stored and annotated in case further sample is obtained to 6 
ensure sufficient material is available for assaying. The annotation of samples, fractions and 7 
pure compounds stored in the centralized repository was managed through a database 8 
implemented by SIPBS and accessible in a secure manner through the SeaBioTech Portal to 9 
all partners involved in sampling, screening and dereplication activities 10 
(http://spider.science.strath.ac.uk/seabiotech/index.php). The SeaBioTech database sample 11 
submission portal ensures tracking of samples and transfer of data between partners ensuring 12 
CPD compliance. The detailed mechanisms to ensure access to the biological resources, and 13 
their associated data, beyond the lifetime of the project will agreed and implemented over the 14 
next 6-10 months.  Each sample was assigned a unique SeaBioTech code and all information 15 
associated to each sample related to parental microorganism, genomics, LCMS, NMR data, 16 
bioactivity results and pharmacological profiling generated during the SeaBioTech 17 
collaboration was entered into the database. In addition, each sample was connected to its 18 
relevant negative control sample (e.g., culture media) that enabled validation and correct 19 
analysis of potentially active entities during bioactivity screening. The database played an 20 
essential role on the prioritization of samples, fractions and compounds for the SeaBioTech 21 
pipeline and represented a valuable asset for the prospective exploitation of the results 22 
obtained by SeaBioTech. The repository of extracts, fractions and pure compounds derived 23 
from underexplored marine microorganisms and the related information managed by the 24 
centralized database represents a valuable infrastructure for future R&D projects in diverse 25 
life science areas. 26 
  27 
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Table 1. Achieved milestones along with the encountered confrontations and some strategies 1 
used to yield to the challenges set by the SeaBioTech consortium.  2 
Milestones achieved  to 
support project challenges WP 
Encountered confrontations and some 
strategies used to yield to the challenge 
1) A reproducible quality of marine resources 
Forty bacterial extremophiles 
were prioritised from a 
collection of ca. 3000 strains 
WP2, 
WP5 
Prioritised isolates were recollected at the same 
seasonal period of the initial collection for 
replication purposes for the repository. 
Five best positive hits were 
identified during primary 
screening 
WP3 Variation of chemical composition was 
encountered due to subtle changes in the 
laboratory conditions, which was monitored by 
metabolomics profiling. 
2) An improved and integrated technology for drug discovery 
Availability of SOP for 
fraction dereplication, 
metabolomic profiling, and 
purification 
WP5 Metabolomic and bioactivity profile preceded 
isolation work on prioritised extracts for the 
pipeline. 
Construction of insertion 
modules and expression 
plasmids finished 
WP4 Alternative expression systems or other 
systems for refolding of the proteins were used. 





Culture of each organism was cultivated under 
a variety of conditions that is metabolomic-
guided to ensure replication of the original 
chemical profile or improvement in the 
concentration of the active constituents. 
Biologically active compounds 
isolated and identified 
WP5 If the selected targets were not affordable in the 
project time frame, suitable alternatives were 
selected as biology-driven construction of 
simpler assay models. 
3) A sustainable mode of supply of raw materials for the industries 




Mitigation of risk by metabolomics analysis 
and re-prioritisation of strains i.e. selection of 
alternative lead strains. 





Targeted gene transfer ensured close link 
between genetic changes to strains and 
subsequent polymer structure and function 
4) A harmonized legal position on marine bioprospecting 
Legal aspects 
harmonised 
WP8 The availability of additional academic 
expertise was enlisted 
Central EU platform WP1 A common board with Bluegenics, PharmaSea, 
Macumba, and SeaBioTech was set-up. 
5) A centralised biobank repository and database of information 
Establishing a metabolomics 
and metagenomics database. 
The repository contains 3209 
strains, 1140 crude samples 
and 606 fractions plated in 





Genomic/metagenomics mining is iterative in 
nature: further rounds of sequencing generated 
leads was supported by metabolomic and 
bioactivity profile 
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